<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Noncoding RNA Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Noncoding RNA Res</journal-id>
<journal-title-group>
<journal-title>Non-coding RNA Research</journal-title>
</journal-title-group>
<issn pub-type="epub">2468-0540</issn>
<publisher>
<publisher-name>KeAi Publishing</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31993547</article-id>
<article-id pub-id-type="pmc">6971376</article-id>
<article-id pub-id-type="publisher-id">S2468-0540(20)30010-X</article-id>
<article-id pub-id-type="doi">10.1016/j.ncrna.2020.01.001</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>MicroRNA-486-5p and microRNA-486-3p: Multifaceted pleiotropic mediators in oncological and non-oncological conditions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="au1">
<name>
<surname>ElKhouly</surname>
<given-names>Aisha M.</given-names>
</name>
<xref ref-type="aff" rid="aff1">a</xref>
</contrib>
<contrib contrib-type="author" id="au2">
<name>
<surname>Youness</surname>
<given-names>R.A.</given-names>
</name>
<email>rana.ahmed-youness@guc.edu.eg</email>
<email>rana.youness21@gmail.com</email>
<xref ref-type="aff" rid="aff2">b</xref>
<xref ref-type="corresp" rid="cor1">∗</xref>
</contrib>
<contrib contrib-type="author" id="au3">
<name>
<surname>Gad</surname>
<given-names>M.Z.</given-names>
</name>
<email>Mohamed.gad@guc.edu.eg</email>
<xref ref-type="aff" rid="aff1">a</xref>
<xref ref-type="corresp" rid="cor2">∗∗</xref>
</contrib>
</contrib-group>
<aff id="aff1"><label>a</label>Biochemistry Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt</aff>
<aff id="aff2"><label>b</label>Pharmaceutical Biology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt</aff>
<author-notes>
<corresp id="cor1"><label>∗</label>Corresponding author. <email>rana.ahmed-youness@guc.edu.eg</email><email>rana.youness21@gmail.com</email></corresp>
<corresp id="cor2"><label>∗∗</label>Corresponding author. <email>Mohamed.gad@guc.edu.eg</email></corresp>
</author-notes>
<pub-date pub-type="pmc-release">
<day>09</day>
<month>1</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
<pub-date pub-type="collection">
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>1</month>
<year>2020</year>
</pub-date>
<volume>5</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>21</lpage>
<history>
<date date-type="received">
<day>20</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>19</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>1</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder></copyright-holder>
<license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
</license>
</permissions>
<abstract id="abs0010">
<p>Despite historically known as “junk” DNA, nowadays non-coding RNA transcripts (ncRNAs) are considered as fundamental players in various physiological and pathological conditions. Nonetheless, any alteration in their expression level has been reported to be directly associated with the incidence and aggressiveness of several diseases. MicroRNAs (miRNAs) are the well-studied members of the ncRNAs family. Several reports have highlighted their crucial roles in the post-transcriptional manipulation of several signaling pathways in different pathological conditions. In this review, our main focus is the multifaceted microRNA-486 (miR-486). miR-486-5p and miR-486-3p have been reported to have central roles in several types oncological and non-oncological conditions such as lung, liver, breast cancers and autism, intervertebral disc degeneration and metabolic syndrome, respectively. Moreover, we spotted the light onto the pleiotropic role of miR-486-5p in acting as competing endogenous RNA with other members of ncRNAs family such as long non-coding RNAs.</p>
</abstract>
<kwd-group id="kwrds0010">
<title>Keywords</title>
<kwd>miR-486-5p</kwd>
<kwd>miR-486-3p</kwd>
<kwd>long non-coding RNAs</kwd>
<kwd>Xist</kwd>
<kwd>Lung cancer</kwd>
<kwd>Breast cancer</kwd>
<kwd>Liver cancer</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="nomen0010">
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="d0010">AGO</term>
<def>
<p id="p0010">Argonaute</p>
</def>
</def-item>
<def-item>
<term id="d0015">ARID1B</term>
<def>
<p id="p0015">AT-rich interaction domain 1B</p>
</def>
</def-item>
<def-item>
<term id="d0020">BC</term>
<def>
<p id="p0020">Breast Cancer</p>
</def>
</def-item>
<def-item>
<term id="d0025">BP</term>
<def>
<p id="p0025">Blood pressure</p>
</def>
</def-item>
<def-item>
<term id="d0030">CAD</term>
<def>
<p id="p0030">Coronary Artery Disease</p>
</def>
</def-item>
<def-item>
<term id="d0035">CRC</term>
<def>
<p id="p0035">Colorectal cancer</p>
</def>
</def-item>
<def-item>
<term id="d0040">CV</term>
<def>
<p id="p0040">Cardiovascular</p>
</def>
</def-item>
<def-item>
<term id="d0045">DDR1</term>
<def>
<p id="p0045">Discoidin domain receptor-1</p>
</def>
</def-item>
<def-item>
<term id="d0050">DLGAP1-AS1</term>
<def>
<p id="p0050">DLGAP1 antisense RNA 1</p>
</def>
</def-item>
<def-item>
<term id="d0055">DGCR8</term>
<def>
<p id="p0055">Drosha-DiGeorge syndrome-critical region gene 8</p>
</def>
</def-item>
<def-item>
<term id="d0060">DOCK1</term>
<def>
<p id="p0060">Dedicator of cytokinesis 1</p>
</def>
</def-item>
<def-item>
<term id="d0065">DSM-5</term>
<def>
<p id="p0065">Disorders Diagnostic and Statistical Manual 5</p>
</def>
</def-item>
<def-item>
<term id="d0070">ECM1</term>
<def>
<p id="p0070">Extracellular matrix protein 1</p>
</def>
</def-item>
<def-item>
<term id="d0075">EMT</term>
<def>
<p id="p0075">Epithelial-mesenchymal transition</p>
</def>
</def-item>
<def-item>
<term id="d0080">eRNAs</term>
<def>
<p id="p0080">Enhancer RNAs</p>
</def>
</def-item>
<def-item>
<term id="d0085">ESCC</term>
<def>
<p id="p0085">Esophageal squamous cell carcinoma</p>
</def>
</def-item>
<def-item>
<term id="d0090">FGF9</term>
<def>
<p id="p0090">Fibroblast growth factor 9</p>
</def>
</def-item>
<def-item>
<term id="d0095">FBN1</term>
<def>
<p id="p0095">Fibrillin-1</p>
</def>
</def-item>
<def-item>
<term id="d0100">FLNA</term>
<def>
<p id="p0100">Filamin A</p>
</def>
</def-item>
<def-item>
<term id="d0105">FOXO1</term>
<def>
<p id="p0105">Forkhead box O1</p>
</def>
</def-item>
<def-item>
<term id="d0110">GC</term>
<def>
<p id="p0110">Gastric carcinoma</p>
</def>
</def-item>
<def-item>
<term id="d0115">HbF</term>
<def>
<p id="p0115">Fetal hemoglobin</p>
</def>
</def-item>
<def-item>
<term id="d0120">HCC</term>
<def>
<p id="p0120">Hepatocellular Carcinoma</p>
</def>
</def-item>
<def-item>
<term id="d0125">HDL</term>
<def>
<p id="p0125">High-density lipoprotein</p>
</def>
</def-item>
<def-item>
<term id="d0130">IDD</term>
<def>
<p id="p0130">Intervertebral Disc Degeneration</p>
</def>
</def-item>
<def-item>
<term id="d0135">IR</term>
<def>
<p id="p0135">Insulin resistance</p>
</def>
</def-item>
<def-item>
<term id="d0140">lncRNA</term>
<def>
<p id="p0140">Long non-coding RNA</p>
</def>
</def-item>
<def-item>
<term id="d0145">LUSC</term>
<def>
<p id="p0145">Lung Squamous cell Carcinoma</p>
</def>
</def-item>
<def-item>
<term id="d0150">Mets</term>
<def>
<p id="p0150">Metabolic syndrome</p>
</def>
</def-item>
<def-item>
<term id="d0155">MMP</term>
<def>
<p id="p0155">Matrix metalloproteinase</p>
</def>
</def-item>
<def-item>
<term id="d0160">miRNA</term>
<def>
<p id="p0160">MicroRNA</p>
</def>
</def-item>
<def-item>
<term id="d0165">micRNA</term>
<def>
<p id="p0165">mRNA-interfering complementary RNA</p>
</def>
</def-item>
<def-item>
<term id="d0170">ncRNAs</term>
<def>
<p id="p0170">Non-Coding RNAs</p>
</def>
</def-item>
<def-item>
<term id="d0175">NP</term>
<def>
<p id="p0175">Nucleus pulposus</p>
</def>
</def-item>
<def-item>
<term id="d0180">NSCLC</term>
<def>
<p id="p0180">Non-Small cell Lung Cancer</p>
</def>
</def-item>
<def-item>
<term id="d0185">NFATc1</term>
<def>
<p id="p0185">Nuclear factor activated T-cell cytoplasmic 1</p>
</def>
</def-item>
<def-item>
<term id="d0190">OSCC</term>
<def>
<p id="p0190">Oral squamous cell</p>
</def>
</def-item>
<def-item>
<term id="d0195">PTC</term>
<def>
<p id="p0195">Papillary Thyroid Cancer</p>
</def>
</def-item>
<def-item>
<term id="d0200">PD</term>
<def>
<p id="p0200">Parkinson's Disease</p>
</def>
</def-item>
<def-item>
<term id="d0205">PLGA</term>
<def>
<p id="p0205">Pegylated poly lactic-co-glycolic acid</p>
</def>
</def-item>
<def-item>
<term id="d0210">PIK3RI</term>
<def>
<p id="p0210">Phosphoinositide-3-Kinase Regulatory Subunit 1</p>
</def>
</def-item>
<def-item>
<term id="d0215">piRNAs</term>
<def>
<p id="p0215">Piwi-associated RNAs</p>
</def>
</def-item>
<def-item>
<term id="d0220">PLAGL2</term>
<def>
<p id="p0220">Pleiomorphic adenoma gene-like 2</p>
</def>
</def-item>
<def-item>
<term id="d0225">Pri-miRNAs</term>
<def>
<p id="p0225">Primary transcripts</p>
</def>
</def-item>
<def-item>
<term id="d0230">RCC</term>
<def>
<p id="p0230">Renal cell carcinoma</p>
</def>
</def-item>
<def-item>
<term id="d0235">RISC</term>
<def>
<p id="p0235">RNA-induced silencing complicated</p>
</def>
</def-item>
<def-item>
<term id="d0240">rRNA</term>
<def>
<p id="p0240">ribosomal RNA</p>
</def>
</def-item>
<def-item>
<term id="d0245">siRNAs</term>
<def>
<p id="p0245">small interfering RNAs</p>
</def>
</def-item>
<def-item>
<term id="d0250">SIRT2</term>
<def>
<p id="p0250">Sirtuin 2</p>
</def>
</def-item>
<def-item>
<term id="d0255">ShRNA</term>
<def>
<p id="p0255">Short hairpin RNA</p>
</def>
</def-item>
<def-item>
<term id="d0260">sncRNA</term>
<def>
<p id="p0260">Short non-coding RNA</p>
</def>
</def-item>
<def-item>
<term id="d0265">snoRNAs</term>
<def>
<p id="p0265">Small nucleolar RNAs</p>
</def>
</def-item>
<def-item>
<term id="d0270">snRNA</term>
<def>
<p id="p0270">Small nuclear RNA</p>
</def>
</def-item>
<def-item>
<term id="d0275">TGF-β activated kinase 1</term>
<def>
<p id="p0275">Transforming growth factor-beta 1</p>
</def>
</def-item>
<def-item>
<term id="d0280">TRBP</term>
<def>
<p id="p0280">TAR RNA-binding protein</p>
</def>
</def-item>
<def-item>
<term id="d0285">tRNA</term>
<def>
<p id="p0285">Transfer RNA</p>
</def>
</def-item>
<def-item>
<term id="d0290">TSP</term>
<def>
<p id="p0290">Thrombospondin</p>
</def>
</def-item>
<def-item>
<term id="d0295">XIST</term>
<def>
<p id="p0295">X-inactive specific transcript</p>
</def>
</def-item>
<def-item>
<term id="d0300">LARC</term>
<def>
<p id="p0300">Locally advanced rectal cancer</p>
</def>
</def-item>
</def-list>
</sec>
<sec id="sec1">
<label>1</label>
<title>The story behind non-coding RNAs (ncRNAs)</title>
<p id="p0305">Many distinctive ncRNA sequences are found in human cells [<xref ref-type="bibr" rid="bib1">1</xref>]. Approximately 30 years ago in the 1980s, ncRNAs' misconception of being ‘junk’ transcriptional products has been changed to be considered as functional regulatory molecules [<xref ref-type="bibr" rid="bib1">1</xref>,<xref ref-type="bibr" rid="bib2">2</xref>]. The first discovered regulatory ncRNA molecule was part of the <italic>MicF</italic> gene [<xref ref-type="bibr" rid="bib1">1</xref>]. MicF RNA includes a stretched sequence that is complementary to the 5′ end region of the ompF mRNA (<italic>OmpF</italic> is a major component of the external layer protein of <italic>Escherichia coli</italic>) and was demonstrated to be a noteworthy player in bacterial cell physiology [<xref ref-type="bibr" rid="bib3">3</xref>,<xref ref-type="bibr" rid="bib4">4</xref>]. MicF RNA was then found to have the potential to regulate various targets by means of various RNA/RNA pairing [<xref ref-type="bibr" rid="bib3">3</xref>]. Yet, the first discovery of the regulatory mechanism of the eukaryotic gene expression by ncRNAs was in the 1990s [<xref ref-type="bibr" rid="bib1">1</xref>]. In 1993, the discovery of the first microRNA (miRNA), lin-4 in <italic>Caenorhabditis elegans</italic> by the Ambros and Ruvkun group has revolutionized the field of molecular biology [<xref ref-type="bibr" rid="bib5">5</xref>]. While the first mammalian miRNA, let-7, was revealed 7 years later [<xref ref-type="bibr" rid="bib6">6</xref>]. Since then ncRNAs and especially miRNAs were the main focus of several researchers until now.</p>
<p id="p0310">ncRNAs were reported to participate in different cellular processes such as transcription, post-transcriptional modifications, and signal transduction networking [<xref ref-type="bibr" rid="bib2">2</xref>]. ncRNAs are divided into house-keeping and regulatory molecules [<xref ref-type="bibr" rid="bib7">7</xref>]. Firstly, the housekeeping ncRNA molecules includes the ribosomal (rRNA), transfer (tRNA), small nuclear (snRNA), and small nucleolar RNAs (snoRNAs) [<xref ref-type="bibr" rid="bib7">7</xref>]. Secondly, the regulatory ncRNAs that can regulate the expression pattern of other coding transcripts includes long non-coding RNAs (lncRNAs) ≥200 nucleotides and short non-coding RNAs (sncRNAs) &lt; 200 nucleotides as shown in <xref ref-type="table" rid="tbl1">Table 1</xref> [<xref ref-type="bibr" rid="bib7">[7]</xref>, <xref ref-type="bibr" rid="bib8">[8]</xref>, <xref ref-type="bibr" rid="bib9">[9]</xref>]. SncRNAs are divided into microRNAs (miRNAs), small interfering RNAs (siRNAs) and piwi-associated RNAs (piRNAs) [<xref ref-type="bibr" rid="bib7">7</xref>]. However, antisense RNAs and enhancer RNAs (eRNAs) are intermediate-sized ncRNA molecules lying at the bay between both classes of lncRNAs and sncRNAs [<xref ref-type="bibr" rid="bib7">7</xref>]. Furthermore, circular RNAs (circRNAs) have lately been identified as a promising class of ncRNAs involved in various biological processes and acts as an sponge for several miRNAs, hindering the miRNAs’ effects on their target transcripts [<xref ref-type="bibr" rid="bib10">10</xref>].<table-wrap id="tbl1" position="float"><label>Table 1</label><caption><p>Types of non-coding RNA molecules.</p></caption><alt-text id="alttext0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="2">Type of ncRNAs<hr/></th><th rowspan="2">Functions</th></tr><tr><th>Housekeeping ncRNAs</th><th>Regulatory ncRNAs</th></tr></thead><tbody><tr><td align="left">rRNAs</td><td></td><td align="left">Involved in mRNA translation</td></tr><tr><td align="left">tRNAs</td><td></td><td align="left">Involved in mRNA translation</td></tr><tr><td align="left">snoRNAs</td><td></td><td align="left">Involved in the modification of rRNAs</td></tr><tr><td align="left">snRNAs</td><td></td><td align="left">Involved in splicing</td></tr><tr><td></td><td align="left">sncRNAs</td><td align="left">mRNA translation regulation or stability</td></tr><tr><td></td><td align="left">lncRNAs</td><td align="left">Chromatin remodeling and transcriptional regulation</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="sec2">
<label>2</label>
<title>MicroRNAs (miRNAs): Master-Maestro of the genome</title>
<p id="p0315">As believed to be the heart of several signaling pathways, miRNAs are single-stranded RNA molecules, subclass from sncRNAs as previously mentioned (~22 nucleotides). miRNAs are branded to be the “Master-Maestro” of the genome where they were reported to post-transcriptionally modulate the expression of approximately 60% of the whole genome in animals, viruses, and plants taking over different metabolic and cellular trails [<xref ref-type="bibr" rid="bib11">[11]</xref>, <xref ref-type="bibr" rid="bib12">[12]</xref>, <xref ref-type="bibr" rid="bib13">[13]</xref>, <xref ref-type="bibr" rid="bib14">[14]</xref>]. Moreover, intracellular miRNAs are ranked as crucial regulators of cellular development and are incorporated in a diversity of biological fates [<xref ref-type="bibr" rid="bib5">5</xref>,<xref ref-type="bibr" rid="bib15">15</xref>]. Extracellular miRNAs as well have been widely discussed as possible biomarkers for several diseases including malignancies and also serve as triggers for cell-cell interaction in several contexts [<xref ref-type="bibr" rid="bib5">5</xref>]. Altered expression levels of miRNAs are accompanied with solid and humoral malignancies [<xref ref-type="bibr" rid="bib15">15</xref>], cardiac illnesses such as hypertrophy and ischemia [<xref ref-type="bibr" rid="bib16">16</xref>] and mental disorders such as schizophrenia or severe depression disorders [<xref ref-type="bibr" rid="bib17">17</xref>]. Hundreds of targets could be regulated by a single miRNA, signifying the multifaceted and combinatorial role of miRNA in regulating mRNA expression [<xref ref-type="bibr" rid="bib14">14</xref>,<xref ref-type="bibr" rid="bib15">15</xref>]. The field of miRNAs is rapidly escalating providing more information about the functional characterization of each miRNA in each disease, thus partially solving the puzzle of multiple diseases‘ molecular pathophysiology.</p>
<sec id="sec2.1">
<label>2.1</label>
<title>miRNAs’ biogenesis</title>
<p id="p0320">The biogenesis of miRNAs is divided into canonical and non-canonical pathways [<xref ref-type="bibr" rid="bib5">5</xref>]. It starts with the processing of RNA polymerase II/III transcripts [<xref ref-type="bibr" rid="bib18">18</xref>]. Approximately half of all presently known miRNAs are intragenic and mostly processed from introns and comparatively few exons of protein coding genes. While the rest minority of the miRNAs are intergenic, transcribed separately of a host gene and governed by their own promoters [<xref ref-type="bibr" rid="bib5">5</xref>]. Often miRNAs are transcribed as a long transcript called clusters that may have comparable seed regions and are considered a family in that case [<xref ref-type="bibr" rid="bib19">19</xref>].</p>
<sec id="sec2.1.1">
<label>2.1.1</label>
<title>Canonical pathway</title>
<p id="p0325">The canonical pathway of the miRNAs biogenesis starts with their transcription to primary miRNA (pri-miRNA) by RNA polymerase II in the nucleus [<xref ref-type="bibr" rid="bib17">[17]</xref>, <xref ref-type="bibr" rid="bib18">[18]</xref>, <xref ref-type="bibr" rid="bib19">[19]</xref>, <xref ref-type="bibr" rid="bib20">[20]</xref>]. These primary transcripts are then processed by the Drosha &amp; DiGeorge syndrome-critical region gene 8 (DGCR8), which produces the precursor miRNA (pre-miRNA, ~70 nucleotide) [<xref ref-type="bibr" rid="bib20">20</xref>]. More specifically, DGCR8 recognizes a pri-miRNA N6-methyladenylated GGAC, whereas Drosha cut the pri-miRNA duplex at the base of the pri-miRNA hairpin structure [<xref ref-type="bibr" rid="bib21">21</xref>]. The pre-miRNA has a brief stem, which is recognized by the nuclear exportin-5 that facilitates its exportation to the cytoplasm as shown in <xref ref-type="fig" rid="fig1">Fig. 1</xref> [<xref ref-type="bibr" rid="bib17">[17]</xref>, <xref ref-type="bibr" rid="bib18">[18]</xref>, <xref ref-type="bibr" rid="bib19">[19]</xref>]. In the cytoplasm, Dicer RNase III induces the processing of miRNA duplexes [<xref ref-type="bibr" rid="bib17">[17]</xref>, <xref ref-type="bibr" rid="bib18">[18]</xref>, <xref ref-type="bibr" rid="bib19">[19]</xref>]. During the cytoplasmic processing of the miRNA, TAR RNA-binding protein (TRBP) and Argonaute (AGO) 1–4 co-operatively resolve the pre-miRNA processing and RNA-induced silencing complicated (RISC) assembly [<xref ref-type="bibr" rid="bib17">[17]</xref>, <xref ref-type="bibr" rid="bib18">[18]</xref>, <xref ref-type="bibr" rid="bib19">[19]</xref>]. After miRNA duplex formation, one strand of the miRNA duplex is separated from this complex, leading to a single-stranded miRNA associated with RISC. But the question now is which strand is loaded to the RISC to form the functional regulatory miRNA-RISC complex?<fig id="fig1"><label>Fig. 1</label><caption><p>Biogenesis of miRNA's Canonical Pathway and mechanism of action.</p><p>The biogenesis of Canonical miRNA is the chief path by which miRNAs are processed. miRNA gene is transcribed in the nucleus to produce primary microRNA (pri-miRNA) that goes through nuclear cleavage to generate a precursor (pre-miRNA). Pre-miRNA is transported to the cytoplasm to be cleaved resulting in miRNA duplex formation. Formerly, the unwinding of miRNA duplex takes place followed by binding to the RISC complex to form a mature miRNA. Each base-pair of a mature miRNA binds to its target mRNA leading to a direct gene silencing through inhibiting translation or mRNA cleavage or mRNA deadenylation.</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"></graphic></fig></p>
<p id="p0330">The -5p or -3p strand choice is partly based on the thermodynamic stability at the 5′ ends of the miRNA duplex or 5′- untranslated region (UTR) at nucleotide position 1 [<xref ref-type="bibr" rid="bib22">22</xref>]. The unloaded strand is named the passenger strand, which unwind from the guide strand (loaded strand) by different mechanisms dependent on complementarity [<xref ref-type="bibr" rid="bib5">5</xref>]. However, recently some miRNAs violate this rule such as miR-486 where both miR-486-5p and miR-486-3p associate with RISC and act as functional regulatory miRNAs.</p>
</sec>
<sec id="sec2.1.2">
<label>2.1.2</label>
<title>Non-canonical pathway</title>
<p id="p0335">The non-canonical pathway of miRNAs’ biogenesis is divided into Drosha/DGCR8-independent or D;icer-independent routes [<xref ref-type="bibr" rid="bib5">5</xref>]. Drosha/DGCR8-independent pathway includes splicing of mRNA introns and their conversion into mirtrons transcripts. Then Drosha/DGCR8 processing step is skipped, where those transcripts are directly transported to the cytoplasm via exportin-1 [<xref ref-type="bibr" rid="bib5">5</xref>]. Alternatively, Dicer-independent miRNAs are handled by Drosha/DGCR8 from endogenous short hairpin RNA (shRNA) transcripts [<xref ref-type="bibr" rid="bib23">23</xref>]. Since those transcripts are not long enough to act as Dicer substrates, in this case AGO2 takes the lead in their cytoplasmic maturation steps [<xref ref-type="bibr" rid="bib24">24</xref>].</p>
</sec>
</sec>
<sec id="sec2.2">
<label>2.2</label>
<title>Mechanism of action</title>
<p id="p0340">Functional miRNAs bind to its target mRNA, where the “seed” sequence which is 2–7 nucleotides from the 5′ end of the miRNA complements to target mRNA sequences, known as miRNA response elements (MREs) [<xref ref-type="bibr" rid="bib25">[25]</xref>, <xref ref-type="bibr" rid="bib26">[26]</xref>, <xref ref-type="bibr" rid="bib27">[27]</xref>]. miRNAs could bind to those MREs in 3′ UTR, 5′UTR, open reading frame (ORF) or its promoter region according to complementary base pairing rules [<xref ref-type="bibr" rid="bib28">28</xref>]. Binding of the miRNA to its target genes' 3′-UTR could be perfect or imperfect complementarity and results in post-transcription silencing through mRNA destabilization, deadenylation,k de-capping and translational repression [<xref ref-type="bibr" rid="bib5">5</xref>,<xref ref-type="bibr" rid="bib16">16</xref>,<xref ref-type="bibr" rid="bib17">17</xref>,<xref ref-type="bibr" rid="bib25">25</xref>,<xref ref-type="bibr" rid="bib29">29</xref>]. Binding of the miRNA to its target gene ORF needs almost ideal complementarity and results in mRNA degradation or cleavage [<xref ref-type="bibr" rid="bib28">28</xref>]. However, the binding of miRNA to its target's promoter region induces transcription, while binding to 5′ UTR leads to either silencing or activation of target gene expression [<xref ref-type="bibr" rid="bib29">29</xref>]. Reports suggest that each miRNA can control various mRNAs and that several miRNAs can target a single mRNA [<xref ref-type="bibr" rid="bib30">30</xref>].</p>
<sec id="sec2.2.1">
<label>2.2.1</label>
<title>Silencing mode</title>
<p id="p0345">The induced silencing mode of the miRNAs to their targets mainly depends on the degree of MRE complementarity. It specifies whether target mRNA will be degraded or AGO2-dependent splicing of target mRNA will occur. A fully complementary interaction activates AGO2 endonuclease to cleave target mRNA [<xref ref-type="bibr" rid="bib31">31</xref>]. The development of a miRISC silencing complex begins with the recruitment by miRISC for the GW182 family of proteins. GW182 structure helps in recruiting numerous effector proteins such as poly (A)-binding protein C which helps in the deadenylation process. Eventually, decapping occurs by the help of decapping protein 2 (DCP2) and derived proteins shadowed by 5′–3′ degradation [<xref ref-type="bibr" rid="bib5">5</xref>].</p>
</sec>
<sec id="sec2.2.2">
<label>2.2.2</label>
<title>Activation mode</title>
<p id="p0350">It has been reported that miRNAs could also induce the expression level of its target mRNAs not only inhibiting their translation [<xref ref-type="bibr" rid="bib5">5</xref>]. Translation activation mediated by miRNA includes AGO2 and Fragile-x-mental retardation related protein 1 (FXR1) rather than GW182. Several miRNAs, have been found to be connected with AGO2 and FXR1 to enable the transcription in the cell cycle arrest mode, yet they suppress transcription in proliferating cells [<xref ref-type="bibr" rid="bib32">32</xref>]. For instance, miR-486-5p was found to induce one of its targets (Insulin-like growth factor-1, IGF-1) in non-cancerous natural killer cells [<xref ref-type="bibr" rid="bib33">33</xref>], yet it was found to repress the same target in cancerous liver cancer cells [<xref ref-type="bibr" rid="bib34">34</xref>]. Also as previously discussed, other forms of miRNA-induced gene expression activation involves binding to the 5′ UTR of mRNAs throughout amino acid starvation [<xref ref-type="bibr" rid="bib35">35</xref>].</p>
</sec>
</sec>
</sec>
<sec id="sec3">
<label>3</label>
<title>miRNAs as prominent players in the battle against malignancies</title>
<p id="p0355">Being a multifactorial player simultaneously targeting several coding genes, this ranks the miRNAs as dominant players in the field of oncology [<xref ref-type="bibr" rid="bib36">36</xref>,<xref ref-type="bibr" rid="bib37">37</xref>]. When a miRNA is able to target/repress several signaling mediators in the oncogenic signaling circuits, this nominates such miRNA to act as a tumor suppressor mediator [<xref ref-type="bibr" rid="bib38">[38]</xref>, <xref ref-type="bibr" rid="bib39">[39]</xref>, <xref ref-type="bibr" rid="bib40">[40]</xref>, <xref ref-type="bibr" rid="bib41">[41]</xref>]. On the contrary, if a miRNA targets the chief tumor suppressor proteins and/or the cell-cycle checkpoint proteins, this nominates such miRNA as an oncogenic miRNA or an oncomiR as <bold>summarized in</bold>
<xref ref-type="table" rid="tbl2">Table 2</xref> [<xref ref-type="bibr" rid="bib42">42</xref>]. The very first study that linked miRNA to cancer was in chronic lymphocytic leukemia patients [<xref ref-type="bibr" rid="bib43">43</xref>]. Where miR-15 and miR-16 were found to be down-regulated [<xref ref-type="bibr" rid="bib43">43</xref>]. One of the top miRNAs that were found to have a paradoxical role, acting as tumor suppressor miRNA or an oncomiR depending on the cellular context, disease condition, expression level of its upstream ncRNAs (lncRNAs or circRNAs) is microRNA-486. Commonly, miR-486 is refereed to miR-486-5p. However, it was reported in literature that miR-486-3p is also acting as a functional regulatory miRNA with aberrant expression in several pathological conditions. In terms of oncology, miR-486-5p was extensively studied in comparison to miR-486-3p. miR-486-5p was found to have a significantly aberrant expression in several solid malignancies such as hepatocellular cancer (HCC), non-small cell lung cancer (NSCLC), breast cancer (BC), esophageal squamous cell carcinoma (ESCC) and pancreatic cancer (PC) [<xref ref-type="bibr" rid="bib44">44</xref>].<table-wrap id="tbl2" position="float"><label>Table 2</label><caption><p>Oncogenic, Ttumor suppressor and Controversial miRNAs in different malignant Phenotypes.</p></caption><alt-text id="alttext0035">Table 2</alt-text><table frame="hsides" rules="groups"><thead><tr><th>miRNAs</th><th>Oncogenic/Tumor Suppressor</th><th>Type of cancer</th><th>Reference</th></tr></thead><tbody><tr><td align="left">miR-17-92 cluster</td><td align="left">Oncogenic</td><td align="left">Lung cancer</td><td align="left">[<xref ref-type="bibr" rid="bib24">24</xref>]</td></tr><tr><td align="left">miR-132</td><td align="left" rowspan="2">Oncogenic</td><td align="left" rowspan="2">Pancreatic adenocarcinoma</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib25">25</xref>]</td></tr><tr><td align="left">miR-212</td></tr><tr><td align="left">miR-195</td><td align="left" rowspan="5">Oncogenic</td><td align="left" rowspan="5">Melanoma adenoma<break></break>Pituitary adenoma</td><td align="left" rowspan="5">[<xref ref-type="bibr" rid="bib26">26</xref>,<xref ref-type="bibr" rid="bib27">27</xref>]</td></tr><tr><td align="left">miR-128a</td></tr><tr><td align="left">miR-155</td></tr><tr><td align="left">miR-516a-3p</td></tr><tr><td align="left">miR-372</td></tr><tr><td align="left">miR-504</td><td align="left" rowspan="5">Oncogenic</td><td align="left" rowspan="5">Osteosarcoma<break></break>Lung cancer<break></break>Neuroblastoma<break></break>Colorectal carcinoma<break></break>Hepatoblastoma<break></break>Breast cancer<break></break></td><td align="left" rowspan="5">[<xref ref-type="bibr" rid="bib28">[28]</xref>, <xref ref-type="bibr" rid="bib29">[29]</xref>, <xref ref-type="bibr" rid="bib30">[30]</xref>, <xref ref-type="bibr" rid="bib31">[31]</xref>]</td></tr><tr><td align="left">miR-25</td></tr><tr><td align="left">miR-30d</td></tr><tr><td align="left">miR-125b</td></tr><tr><td align="left">miR-1285</td></tr><tr><td align="left">miR-24</td><td align="left" rowspan="2">Oncogenic</td><td align="left" rowspan="2">Human diploid fibroblasts<break></break>Cervical carcinoma<break></break>Mouse embryonic fibroblasts</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib32">32</xref>,<xref ref-type="bibr" rid="bib33">33</xref>]</td></tr><tr><td align="left">miR-31</td></tr><tr><td align="left">miR-21</td><td align="left" rowspan="3">Oncogenic</td><td align="left" rowspan="3">Prostate cancer<break></break>Gastric cancer</td><td align="left" rowspan="3">[<xref ref-type="bibr" rid="bib34">34</xref>,<xref ref-type="bibr" rid="bib35">35</xref>]</td></tr><tr><td align="left">miR 221/222 cluster</td></tr><tr><td align="left">miR-25</td></tr><tr><td align="left">miR-10b</td><td align="left" rowspan="3">Oncogenic</td><td align="left" rowspan="3">Breast Cancer</td><td align="left" rowspan="3">[<xref ref-type="bibr" rid="bib36">36</xref>,<xref ref-type="bibr" rid="bib37">37</xref>]</td></tr><tr><td align="left">miR-373</td></tr><tr><td align="left">miR-520c</td></tr><tr><td align="left">miR-223</td><td align="left">Oncogenic</td><td align="left">Gastric Cancer</td><td align="left">[<xref ref-type="bibr" rid="bib38">38</xref>]</td></tr><tr><td align="left">miR-31</td><td align="left" rowspan="2">Oncogenic</td><td align="left" rowspan="2">Lung cancer cells</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib39">39</xref>,<xref ref-type="bibr" rid="bib40">40</xref>]</td></tr><tr><td align="left">miR-411</td></tr><tr><td align="left">miR-217</td><td align="left">Tumor Suppressor</td><td align="left">Pancreatic ductal adenocarcinoma</td><td align="left">[<xref ref-type="bibr" rid="bib41">41</xref>]</td></tr><tr><td align="left">miR-335</td><td align="left" rowspan="2">Tumor Suppressor</td><td align="left" rowspan="2">Breast Cancer</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib37">37</xref>,<xref ref-type="bibr" rid="bib42">42</xref>]</td></tr><tr><td align="left">miR-101</td></tr><tr><td align="left">miR-34a</td><td align="left">Tumor Suppressor</td><td align="left">Pancreatic cancer</td><td align="left">[<xref ref-type="bibr" rid="bib43">43</xref>]</td></tr><tr><td align="left">miR-143</td><td align="left" rowspan="2">Tumor Suppressor</td><td align="left" rowspan="2">Colon cancer</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib44">44</xref>]</td></tr><tr><td align="left">miR-145</td></tr><tr><td align="left">miR-15a</td><td align="left" rowspan="3">Tumor Suppressor</td><td align="left" rowspan="3">Leukemia</td><td align="left" rowspan="3">[<xref ref-type="bibr" rid="bib45">45</xref>,<xref ref-type="bibr" rid="bib46">46</xref>]</td></tr><tr><td align="left">miR 16-1</td></tr><tr><td align="left">miR-495</td></tr><tr><td align="left">miR-203</td><td align="left" rowspan="2">Tumor Suppressor</td><td align="left" rowspan="2">Lung cancer</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib47">47</xref>,<xref ref-type="bibr" rid="bib48">48</xref>]</td></tr><tr><td align="left">miR-218</td></tr><tr><td align="left">miR-451</td><td align="left">Tumor Suppressor</td><td align="left">Non-small cell lung cancer</td><td align="left">[<xref ref-type="bibr" rid="bib49">49</xref>]</td></tr><tr><td align="left">miR-96</td><td align="left">Tumor Suppressor</td><td align="left">Pancreatic cancer</td><td align="left">[<xref ref-type="bibr" rid="bib50">50</xref>]</td></tr><tr><td align="left">miR-150</td><td align="left">Tumor Suppressor</td><td align="left">Malignant lymphoma</td><td align="left">[<xref ref-type="bibr" rid="bib51">51</xref>]</td></tr><tr><td align="left">miR‐122</td><td align="left">Tumor Suppressor</td><td align="left">Hepatocellular carcinoma</td><td align="left">[<xref ref-type="bibr" rid="bib52">52</xref>]</td></tr><tr><td align="left">miR-143</td><td align="left" rowspan="2">Tumor Suppressor</td><td align="left" rowspan="2">Bladder Cancer</td><td align="left" rowspan="2">[<xref ref-type="bibr" rid="bib53">53</xref>,<xref ref-type="bibr" rid="bib54">54</xref>]</td></tr><tr><td align="left">miR-99a-5p</td></tr><tr><td align="left">miR-7</td><td align="left">Controversial</td><td align="left">Lung cancers</td><td align="left">[<xref ref-type="bibr" rid="bib55">[55]</xref>, <xref ref-type="bibr" rid="bib56">[56]</xref>, <xref ref-type="bibr" rid="bib57">[57]</xref>]</td></tr><tr><td align="left">miR-486</td><td align="left">Controversial</td><td align="left">Breast Cancer<break></break>Prostate Cancer</td><td align="left">[<xref ref-type="bibr" rid="bib58">58</xref>,<xref ref-type="bibr" rid="bib59">59</xref>]</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="sec4">
<label>4</label>
<title>miR-486: chromosomal location, behavior and functions</title>
<p id="p0360">miR-486 is encoded by the MIR486-1 gene in the human genome. Its genomic location is on chromosome 8 (8p11.21) as shown in <xref ref-type="fig" rid="fig2">Fig. 2</xref>. This region in the genome is called a deletion region having the most potent tumor suppressor genes [<xref ref-type="bibr" rid="bib34">34</xref>]. As previously described, there are 2 mature miRNA strands originating from opposite arms of the same pre-miR-486 and are denoted with a -3p or -5p suffix as shown in <xref ref-type="table" rid="tbl3">Table 3</xref> miR-486-5p and miR-486-3p shows a controversial role in various pathological conditions [<xref ref-type="bibr" rid="bib45">45</xref>,<xref ref-type="bibr" rid="bib46">46</xref>]. In many forms of cancers, they could act as a tumor-suppressive miRNA through inhibiting the migration and invasion capacities of several cancers [<xref ref-type="bibr" rid="bib47">47</xref>,<xref ref-type="bibr" rid="bib48">48</xref>]. On the contrary, miR-486-5p showed its oncogenic properties in other forms of cancers such as PC [<xref ref-type="bibr" rid="bib46">46</xref>]. Moreover, miR-486-5p and miR-486-3p were found to have a high potential to act as diagnostic and prognostic marker in several diseases such as cancers and metabolic syndromes (MetS). On the national level, miR-486-5p was reported to act as a promising prognostic factor for major public health issues such as insulin resistance (IR) and elevated blood pressure (BP) among the Egyptian males [<xref ref-type="bibr" rid="bib49">49</xref>]. Therefore this review focuses on the multifaceted miR-486-5p and miR-486-3p and its differential expression and mechanism of actions in several cancers and pathological conditions.<fig id="fig2"><label>Fig. 2</label><caption><p>Chromosomal location of miR-486-5p.</p><p>Schematic representation of miR-486-5p gene locus; chromosomal mapping showed that miR-486 gene is located on somatic chromosome 8, long arm, region 11, band 21 (8p11.21).</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"></graphic></fig><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><p>The difference in sequence of miR-486-5p and miR-486-3p.</p></caption><alt-text id="alttext0040">Table 3</alt-text><table frame="hsides" rules="groups"><thead><tr><th>miR-486-5p Sequence</th><th>miR-486-3p sequence</th></tr></thead><tbody><tr><td align="left">0- UCCUGUACUGAGCUGCCCCGAG -22</td><td align="left">42- CGGGGCAGCUCAGUACAGGAUA -64</td></tr></tbody></table></table-wrap></p>
</sec>
<sec id="sec5">
<label>5</label>
<title>miR-486-5p role in different oncological phenotypes</title>
<sec id="sec5.1">
<label>5.1</label>
<title>Non-small-cell lung cancer (NSCLC)</title>
<p id="p0365">NSCLC is considered one of the most prevalent types of lung cancer [<xref ref-type="bibr" rid="bib50">50</xref>]. In NSCLC, miR-486-5p was reported to be downregulated in NSCLC patients and cell lines (A549 cells) [<xref ref-type="bibr" rid="bib51">51</xref>]. This was believed to be related to the abnormal methylation of ANK1 promoter that harbors the same chromosomal location of miR-486-5p (8p11.21) [<xref ref-type="bibr" rid="bib52">52</xref>]. miR-486-5p gene is located in the last intron of ANK1 [<xref ref-type="bibr" rid="bib52">52</xref>]. Furthermore, miR-486-5p levels in NSCLC were directly correlated with the prognosis of the diseases where patients with low levels of miR-486-5p showed poor prognosis. NSCLC treatment protocol mainly includes Cisplatin as a potent chemotherapeutic agent [<xref ref-type="bibr" rid="bib51">51</xref>]. However, the rise of Cisplatin resistance has become one of the main obstacles for effective treatment of NSCLC patients. miR-486-5p is believed to have a role in chemo-resistance of several cancers [<xref ref-type="bibr" rid="bib51">51</xref>]. This was explained by twinfilin actin-binding protein 1 (TWF1) which is a direct target gene for miR-486-5p in HEK-293T cells and plays an undisputable role in tumor invasion and chemotherapy resistance [<xref ref-type="bibr" rid="bib48">48</xref>,<xref ref-type="bibr" rid="bib49">49</xref>,<xref ref-type="bibr" rid="bib51">51</xref>]. TWF1 suppression by miR-486-5p leads to increase NSCLC cell line (A549 cells) susceptibility to Cisplatin [<xref ref-type="bibr" rid="bib51">51</xref>]. Moreover, miR-486-5p's role in managing Cisplatin resistance was investigated <italic>in vivo</italic>, revealing that miR-486-5p expression has increased the NSCLC tumor sensitivity to cisplatin treatment by reducing NSCLC tumor size in nude mice [<xref ref-type="bibr" rid="bib51">51</xref>]. Hence miR-486-5p is considered to be an effective therapeutic agent in managing Cisplatin resistant NSCLC [<xref ref-type="bibr" rid="bib51">51</xref>]. Grb2-Associated Binding Protein 2 (GAB2) is another direct target gene for miR-486-5p and it is usually up-regulated in numerous human malignancies [<xref ref-type="bibr" rid="bib53">53</xref>]. GAB2 functions as a mediator for vital cellular processes containing proliferation and migration [<xref ref-type="bibr" rid="bib52">52</xref>]. Forced expression of miR-486-5p in SPC-A1 and A549 cell lines leads to inhibition of GAB2, thus preventing the metastasis and progression of NSCLC [<xref ref-type="bibr" rid="bib53">53</xref>]. Therefore, this shows the potential therapeutic and prognostic roles of miR-486-5p in NSCLC patients.</p>
</sec>
<sec id="sec5.2">
<label>5.2</label>
<title>Lung squamous cell carcinoma (LUSC)</title>
<p id="p0370">LUSC is the 2nd most common cancer among the world, yet until now it lacks a specific, reliable and detective diagnostic biomarker [<xref ref-type="bibr" rid="bib54">54</xref>]. miRNAs are fortunately produced in extracellular fluids, which highly appoints miRNAs as easily detectable biomarkers for various diseases [<xref ref-type="bibr" rid="bib5">5</xref>]. miR-486-5p is down-regulated in LUSC patients compared to healthy controls and it was found to be also down-regulated in LUSC cell lines such as NCI–H520, human bronchial epithelial cells and B(a)P malignantly transformed HBE cells which supports its ability to act as a diagnostic marker for LUSC [<xref ref-type="bibr" rid="bib54">54</xref>]. Functionally, miR-486-5p regulates the aggressive oncogenic signaling pathway; PI3K/AKT/mTOR causing the hindrance of LUSC development [<xref ref-type="bibr" rid="bib54">54</xref>].</p>
</sec>
<sec id="sec5.3">
<label>5.3</label>
<title>Colorectal cancer (CRC)</title>
<p id="p0375">One of the main reasons for cancer-related deaths is CRC [<xref ref-type="bibr" rid="bib55">55</xref>,<xref ref-type="bibr" rid="bib56">56</xref>]. The early detection of CRC using biomarkers could help to decrease the death rate through preventing the disease progression [<xref ref-type="bibr" rid="bib55">55</xref>,<xref ref-type="bibr" rid="bib57">57</xref>]. Circulating exosomal miRNAs could act as CRC biomarkers [<xref ref-type="bibr" rid="bib58">58</xref>,<xref ref-type="bibr" rid="bib59">59</xref>]. Some studies reported that the circulating exosomal miR-486-5p levels were highly low in locally advanced rectal cancer (LARC) cell line (LoVo cells) with a high metastatic grade. Additionally, other studies reported that miR-486-5p CRC tissues’ expression was also highly repressed in early stage CRC patients [<xref ref-type="bibr" rid="bib57">57</xref>,<xref ref-type="bibr" rid="bib60">60</xref>]. Collectively, exosomal miR-486-5p is believed to act as a circulating marker for high-risk LARC [<xref ref-type="bibr" rid="bib57">57</xref>]. In an explanation for the reduced miR-486-5p expression in CRC patients and cell lines and similar to NSCLC, miR-486-5p expression was found to be lowered in CRC tissues and cell lines (HT29 and SW480 cells) due to hyper-methylation of miR-486-5p promoter [<xref ref-type="bibr" rid="bib56">56</xref>]. On the functional level, forcing miR-486-5p expression resulted in suppression of CRC invasion both <italic>in vitro</italic> and <italic>in vivo</italic> by directly targeting pleiomorphic adenoma gene-like 2 (<italic>PLAGL2</italic>) which eventually represses 2 of the most vital oncogenic pathways β-catenin and Insulin Growth Factor 2 signaling pathways [<xref ref-type="bibr" rid="bib56">56</xref>]. Collectively, miR-486-5p could act as a potential therapeutic and diagnostic biomarker for CRC patients [<xref ref-type="bibr" rid="bib56">56</xref>].</p>
</sec>
<sec id="sec5.4">
<label>5.4</label>
<title>Breast cancer (BC)</title>
<p id="p0380">BC is considered to be one of the most widely spread cancers between women worldwide [<xref ref-type="bibr" rid="bib37">37</xref>]. miR-486-5p is one of the well-studied miRNAs in BC. It was found to be strongly down-regulated in BC patients and BC cell lines (MDA-MB231, MCF-7, SK-BR-3, and T47D cells) [<xref ref-type="bibr" rid="bib61">61</xref>,<xref ref-type="bibr" rid="bib62">62</xref>]. Functionally, ectopic expression of miR-486-5p causes the repression of the oncogenes <italic>PIM1</italic> and <italic>PTEN</italic> which eventually results in total abrogation of BC proliferation [<xref ref-type="bibr" rid="bib61">61</xref>,<xref ref-type="bibr" rid="bib62">62</xref>]. Moreover, miR-486-5p also directly targets dedicator of cytokinesis 1 (DOCK1) which is directly fueling BC motility and invasion capacities through activating the Dock1/NF-ƙB/Snail pathway [<xref ref-type="bibr" rid="bib63">63</xref>]. Thus miR-486-5p is found to repress BC progression, proliferation, migration and invasion potentials through targeting several oncogenes and affecting multiple signaling pathways simultaneously [<xref ref-type="bibr" rid="bib63">63</xref>]. Nevertheless, miR-486-5p role in BC is not only restricted to the malignant phenotype of the disease. However, miR-486-5p also affects the tumor microenvironment conditions and the immunogenic profile of BC patients. It was found that miR-486-5p directly targets the immune-suppressive Interleukin-22 (IL-22), thus alleviating the immune suppressive nature of the BC tumor microenvironment [<xref ref-type="bibr" rid="bib63">63</xref>]. Moreover, our research group has recently highlighted the potential role of miR-486-5p in inducing the activating immune ligands MICA, MICB and CD155 in order to increase the recognition ability of BC cells to the cytotoxic T lymphoctyes and natural killer cells in BC patients (unpublished data). Nonetheless, another study revealed the significance of miR-486-5p to serve as a useful marker for documenting BC high-risk patients [<xref ref-type="bibr" rid="bib62">62</xref>]. Collectively, miR-486-5p could serve as a diagnostic marker for BC patients, potential therapeutic approach revealing the malignant phenotypic behavior of BC cells, alleviating the immune-suppressive tumor microenvironment and boosting the immunogenic recognition of BC cells by the immune system.</p>
</sec>
<sec id="sec5.5">
<label>5.5</label>
<title>Hepatocellular carcinoma (HCC)</title>
<p id="p0385">HCC is the most common primary liver malignancy and is a prominent contributor to cancer mortalities worldwide [<xref ref-type="bibr" rid="bib64">64</xref>]. Our research group has found that miR-486-5p was down-regulated in HCC liver tissues and cell lines (Huh-7 cells), where its ectopic expression was found to block one of the most aggressive deregulated oncogenic signaling pathway in HCC patients. Moreover, miR-486-5p was also found to repress IGF-1R downstream signaling mediators known as mTOR, STAT3 and c-Myc [<xref ref-type="bibr" rid="bib34">34</xref>,<xref ref-type="bibr" rid="bib61">61</xref>]. Moreover, miR-486-5p was also found to boost the chief l2player of the innate immune system which is the natural killer cells of HCC patients mainly through augmenting its killing capacity against HCC cell lines through inducing the expression levels of perforins [<xref ref-type="bibr" rid="bib33">33</xref>]. Therefore, this shows the potential role of miR-486-5p in HCC where it dually acts as a tumor suppressor miRNA and an enhancer immune surveillance capabilities of HCC patients through directly increasing the cytotoxic potential of natural killer cells.</p>
</sec>
<sec id="sec5.6">
<label>5.6</label>
<title>Renal cell carcinoma (RCC)</title>
<p id="p0390">RCC is a mutual kidney tumor in humans [<xref ref-type="bibr" rid="bib65">65</xref>]. Surgical resection is a preferred choice in the early stage of RCC [<xref ref-type="bibr" rid="bib66">66</xref>]. However, therapy resistance is the major obstacle in the late stage of RCC [<xref ref-type="bibr" rid="bib67">67</xref>]. Therefore, it is important to find new targets in RCC treatment [<xref ref-type="bibr" rid="bib68">68</xref>]. miR-486-5p expression is found to be lowered in RCC patients and cell lines (786-O, GRC-1, A-498, ACHN, Caki-2, 786-P, SK-RC-42, and Ketr3 cells) [<xref ref-type="bibr" rid="bib47">47</xref>]. Forcing its expression leads to the inhibition of RCC cell proliferation and the increase of cell apoptosis through suppressing Transforming growth factor-beta 1 (TGF-β activated kinase 1) [<xref ref-type="bibr" rid="bib47">47</xref>] thus crystallizes the tumor suppressor potential of miR-486-5p in RCC patients.</p>
</sec>
<sec id="sec5.7">
<label>5.7</label>
<title>Gastric cancer (GC)/Esophageal squamous cell carcinoma (ESCC)</title>
<p id="p0395">The highest incidence rates for GC/ESCC were found to be in eastern Asia, eastern and southern Africa. The late stage of GC/ESCC always has restricted treatment options. A recent study proved that miR-486-5p was chiefly presented in the cytoplasm of cells and its expression was reduced in the majority of ESCC and GC [<xref ref-type="bibr" rid="bib47">47</xref>]. Phosphoinositide-3-Kinase Regulatory Subunit 1 (PIK3RI) and fibroblast growth factor 9 (FGF9) were found as direct targets for miR-486-5p in GC [<xref ref-type="bibr" rid="bib47">47</xref>,<xref ref-type="bibr" rid="bib69">69</xref>,<xref ref-type="bibr" rid="bib70">70</xref>]. As previously described, a frequent characteristic in plentiful of human malignancies is the deregulation of the PI3K/Akt pathway leading to cancer progression [<xref ref-type="bibr" rid="bib71">71</xref>]. FGF9 is secreted from cancer-associated fibroblasts that stimulate GC cells invasiveness [<xref ref-type="bibr" rid="bib72">72</xref>]. Thus this nominates miR-486-5p as a tumor suppressor miRNA through repressing PI3KR1 and FGF9 in GC and ESCC cells [<xref ref-type="bibr" rid="bib47">47</xref>].</p>
</sec>
<sec id="sec5.8">
<label>5.8</label>
<title>Papillary thyroid cancer (PTC)</title>
<p id="p0400">The most severe malignancy of the endocrine system is thyroid cancer [<xref ref-type="bibr" rid="bib73">73</xref>]. About 80% of the world's diagnosed thyroid cancers are PTC [<xref ref-type="bibr" rid="bib74">74</xref>]. New studies have shown that KIAA1199 also plays a key role in the development of PTC inducing its invasion and metastatic potentials [<xref ref-type="bibr" rid="bib74">74</xref>]. Moreover, KIAA1199 switched on several signaling pathways such as the Wnt/β-catenin and induces the enzymatic activities of matrix metalloproteinase (MMP), which relate to the epithelial-mesenchymal transition (EMT) [<xref ref-type="bibr" rid="bib74">74</xref>]. It was found that KIAA1199 is expressively up-regulated in PTC tissues with a negative correlation with miR-486-5p expression [<xref ref-type="bibr" rid="bib74">74</xref>]. This study revealed that KIAA1199 is a direct target of miR-486-5p with and thus ectopic expression of miR-486-5p resulted in a marked repression of KIAA1199 mRNA and protein expression helping in averting PTC invasion and metastasis [<xref ref-type="bibr" rid="bib74">74</xref>]. Another study unraveled another onogenic target of miR-486-5p which is Fibrillin-1 (FBN1) [<xref ref-type="bibr" rid="bib75">75</xref>] and thus also confirming the tumor suppressor activity of miR-486-5p in PTC patients.</p>
</sec>
<sec id="sec5.9">
<label>5.9</label>
<title>Ovarian cancer</title>
<p id="p0405">Ovarian cancer is considered to be one of the utmost common gynecological malignant tumors [<xref ref-type="bibr" rid="bib76">76</xref>]. Estrogen and progesterone are being secreted by the ovaries, where estrogen plays a dominant role in ovarian tumor growth and metastasis [<xref ref-type="bibr" rid="bib76">76</xref>]. It has been found that the hyper-activation of estrogen receptor alpha (ERα) causes changes on the genetic and epigenetic levels in ovarian cancer cells [<xref ref-type="bibr" rid="bib76">76</xref>]. ER signaling regulates the expression of Olfactomedin 4 (<italic>OLFM4</italic>) in ovarian serous adenocarcinoma. It has been proven that gynecological tumors especially serous adenocarcinoma tissues have aberrant OLFM4 expression [<xref ref-type="bibr" rid="bib76">76</xref>]. Impairment of the expression of ERα-mediated OLFM4 facilitates malignant development of ovarian serous adenocarcinoma [<xref ref-type="bibr" rid="bib77">77</xref>]. In ovarian serous adenocarcinoma, the down-regulated miR-486-5p potentially targets OLFM4 in SKOV3 ovarian cancer cell lines, repressing its expression level and activity and thus repressing ovarian cancer progression [<xref ref-type="bibr" rid="bib76">76</xref>].</p>
</sec>
<sec id="sec5.10">
<label>5.10</label>
<title>Leukemia</title>
<p id="p0410">Leukemia is known for its atypical blood precursor cells proliferation of myeloid or lymphoid nature [<xref ref-type="bibr" rid="bib78">78</xref>]. Lately, studies have shown that miRNAs and lncRNAs could act as prognostic and diagnostic biomarkers for leukemic patients [<xref ref-type="bibr" rid="bib79">79</xref>,<xref ref-type="bibr" rid="bib80">80</xref>]. miR-486-5p was found to be down-regulated in leukemic cell lines (K562, Kasumi-1, and THP-1 cells) [<xref ref-type="bibr" rid="bib81">81</xref>]. miR-486-5p showed an interaction with the 3′-UTR of forkhead box O1(FOXO1) [<xref ref-type="bibr" rid="bib81">81</xref>]. FOXO1 existence during oxidative stress leads to apoptotic cell injury [<xref ref-type="bibr" rid="bib82">82</xref>]. Thus miR-486-5p ectopic-expression leads to an increase in the apoptosis of leukemia cells by targeting FOXO1 [<xref ref-type="bibr" rid="bib81">81</xref>].</p>
</sec>
<sec id="sec5.11">
<label>5.11</label>
<title>Prostate cancer (PC)</title>
<p id="p0415">The most common malignancy among men is PC [<xref ref-type="bibr" rid="bib83">83</xref>]. Human PC gene expression profiling has shown several miRNAs involvements where miR-486-5p was on top of the list. On the contrary to other solid malignancies mentioned above and summarized in <xref ref-type="fig" rid="fig3">Fig. 3</xref>, miR-486-5p was found to be over-expressed in PC tissues and cell lines (DU145, PC-3, and LnCap) [<xref ref-type="bibr" rid="bib83">83</xref>]. miR-486-5p overexpression stimulates different oncogenic pathways through suppressing FOXO1, PTEN and SMAD2 [<xref ref-type="bibr" rid="bib83">83</xref>]. Where PTEN and FOXO1 act as negative regulators for PI3K/AKT signaling straightly suppressing the proliferation [<xref ref-type="bibr" rid="bib83">83</xref>]. Besides, SMAD2 acts as a tumor suppressor by taking part in the stem cell compartment of prostate cancer [<xref ref-type="bibr" rid="bib83">83</xref>]. <italic>In vivo</italic>, it was proven that miR-486-5p acts as a oncomiR in PC, as it plays an important role in PC pathogenicity [<xref ref-type="bibr" rid="bib83">83</xref>].<fig id="fig3"><label>Fig. 3</label><caption><p>Multi-functional Role of miR-486-3p in simultaneously targeting several targets in different cellular contexts.</p><p>miR-486-3p has several targets in different malignant and non-malignant conditions. It modulates the expression of several target proteins such as BCL11A, TSP-2, ECM1, FLNA, DDR1, SIRT2 and ARID1B in different body compartments as indicated in the diagram.</p></caption><alt-text id="alttext0020">Fig. 3</alt-text><graphic xlink:href="gr3"></graphic></fig></p>
</sec>
</sec>
<sec id="sec6">
<label>6</label>
<title>miR-486-3p role in different oncological phenotypes</title>
<sec id="sec6.1">
<label>6.1</label>
<title>Oral squamous cell carcinoma (OSCC)</title>
<p id="p0420">OSCC, is one of the world's deadly cancers, with a significant increase in incidence and mortality in the last century [<xref ref-type="bibr" rid="bib84">84</xref>]. Betel quid chewing was acknowledged as a significant contributor to the incidence and mortality rate of oral cancer [<xref ref-type="bibr" rid="bib85">85</xref>]. miR-486-3p expression was found to be down-regulated in OSCC [<xref ref-type="bibr" rid="bib86">86</xref>]. Discoidin domain receptor-1(DDR1) is a tyrosine kinase and was reported to be up-regulated in OSCC tissues and cell lines (OEC-M1 and TW2-6) leading to tumor progression [<xref ref-type="bibr" rid="bib86">86</xref>]. Fortunately, DDR1 was found to be a direct gene target for tumor suppressor miR-486-3p [<xref ref-type="bibr" rid="bib86">86</xref>]. As it was mentioned above that ANK1 irregular epigenetic modifications could lead to suppression of miR-486-5p in NSCLC [<xref ref-type="bibr" rid="bib86">86</xref>]. Accordingly, hyper-methylation of ANK1 promoter by DNMT3B which is found in arecoline (a major component of betel quid chewing) leads to a reduction of ANK1 and miR-486-3p expression subsequently leading to DDR1 expression [<xref ref-type="bibr" rid="bib86">86</xref>]. Therefore restoring the expression of miR-486-3p in OSCC patients might lead to apoptosis of OSCC cancer cells and therapeutically alleviating OSCC progression [<xref ref-type="bibr" rid="bib86">86</xref>].</p>
</sec>
<sec id="sec6.2">
<label>6.2</label>
<title>Lung cancer</title>
<p id="p0425">As mentioned earlier, lung cancer is the most common malignancy worldwide. It is also the major cause of cancer-related death among males, and the world's 2nd leading cause of cancer-related deaths among females [<xref ref-type="bibr" rid="bib87">87</xref>]. The matricellular glycoprotein thrombospondin-2 (TSP-2) is found to regulate numerous biological processes and play a dominant role in the development and metastasis of lung cancer [<xref ref-type="bibr" rid="bib88">88</xref>]. Additionally, TSP-2 expression is strongly associated with lung cancer stage [<xref ref-type="bibr" rid="bib88">88</xref>]. It was recently discovered that TSP-2 also stimulates osteoclastogenesis through the RANKL-dependent pathway and that TSP-2-mediated osteoclastogenesis encompasses the transactivation of the Nuclear factor activated T-cell cytoplasmic 1 (NFATc1) through repression of miR-486-3p expression [<xref ref-type="bibr" rid="bib88">88</xref>]. Therefore, restoring the expression of miR-486-3p leads to the abrogation of TSP-2 effects and inhibition of osteolytic metastasis <italic>in vivo</italic> [<xref ref-type="bibr" rid="bib88">88</xref>].</p>
</sec>
<sec id="sec6.3">
<label>6.3</label>
<title>Cervical cancer (CC)</title>
<p id="p0430">Cervical cancer (CC) is the 4th common gynecological malignancy and the 2nd most common cancer in developing countries [<xref ref-type="bibr" rid="bib89">89</xref>]. miR-486-3p expression is found to be reduced in CC besides being correlated with metastasis in those patients [<xref ref-type="bibr" rid="bib90">90</xref>]. Extracellular matrix protein-1 (ECM-1) has been predicted and validated as a miR-486-3p target gene as shown in <xref ref-type="fig" rid="fig4">Fig. 4</xref> [<xref ref-type="bibr" rid="bib90">90</xref>]. Eventually, cell growth and metastasis were inhibited by miR-486-3p ectopic-expression [<xref ref-type="bibr" rid="bib90">90</xref>]. miR-486-3p is a tumor suppressor miRNA and its induction is a possible strategy for inhibiting the development of CC [<xref ref-type="bibr" rid="bib90">90</xref>].<fig id="fig4"><label>Fig. 4</label><caption><p>The pleiotropic role of miR-486-5p in manipulating several target genes in different cellular contexts.</p><p>miR-486-5p has several targets in different malignant and non-malignant conditions. It modulates the expression of several target proteins such as TGF-β activated kinase1, PTEN, DOCK1,IGF- signaling pathway, KIAA1199, FBN1, FOXO1, PI3K-AKT,SMAD2, FGF9, PIK3RI, TWF1, GAB2, OLFM4 and PLAGL2.</p></caption><alt-text id="alttext0025">Fig. 4</alt-text><graphic xlink:href="gr4"></graphic></fig></p>
</sec>
<sec id="sec6.4">
<label>6.4</label>
<title>Laryngeal squamous cell carcinoma (LSCC)</title>
<p id="p0435">LSCC is the world's 2nd most widely diagnosed head and neck cancer [<xref ref-type="bibr" rid="bib91">91</xref>]. Since Circular RNA (circRNA) is a vital regulator of miRNA activity [<xref ref-type="bibr" rid="bib92">92</xref>]. circRNAs is believed to have fundamental biological roles in the migration and development of cancer [<xref ref-type="bibr" rid="bib93">93</xref>]. Filamin A (FLNA) is essential for organogenesis during development, due to its capability to induce cell migration through its actin-binding properties [<xref ref-type="bibr" rid="bib94">94</xref>]. In LSCC tissues and cell lines (Tu212, SCC-2 and SCC-40), circFLNAs were found to be up-regulated and sponge miR-486-3p [<xref ref-type="bibr" rid="bib93">93</xref>]. The results also showed that miR-486-3p reduced LSCC cell migration by negative moderation of FLNA protein level and its level of expression was associated with lymph node metastasis [<xref ref-type="bibr" rid="bib93">93</xref>]. These outcomes recommend that miR-486-3p have an important role in LSCC migration [<xref ref-type="bibr" rid="bib93">93</xref>].</p>
</sec>
</sec>
<sec id="sec7">
<label>7</label>
<title>miR-486-5p role in non-oncological phenotypes</title>
<sec id="sec7.1">
<label>7.1</label>
<title>Metabolic syndrome (MetS)</title>
<p id="p0440">MetS is a cluster of various interrelated cardiovascular (CV) and cerebrovascular disease risk factors including visceral obesity, insulin resistance (IR) and elevated blood pressure (BP) [<xref ref-type="bibr" rid="bib95">95</xref>]. It was reported that the circulating levels of muscle-enriched miR-486-5p is declined in acute and chronic exercises due to metabolic changes throughout exercise and adaptation persuaded by training [<xref ref-type="bibr" rid="bib96">96</xref>]. Another study reported the elevation of serum levels of miR-486-5p in metabolic syndrome Egyptian male patients draws a hypothesis that it could be used as an early biomarker for the diagnosis and prognosis of metabolic syndrome as previously mentioned [<xref ref-type="bibr" rid="bib49">49</xref>]. miR-486-5p was found to be up-regulated in the plasma of patients having visceral obesity [<xref ref-type="bibr" rid="bib49">49</xref>]. A high carbohydrate diet which is a cause for visceral obesity induces the expression of miR-486-5p [<xref ref-type="bibr" rid="bib49">49</xref>]. On the molecular level, FOXO1 is an insulin mediator and was found to be targeted by miR-486-5p [<xref ref-type="bibr" rid="bib81">81</xref>]. Thus upon connecting the lines, miR-486-5p could be used as a biomarker to screen obesity in children and thus reducing the risk of having diabetes in adulthood [<xref ref-type="bibr" rid="bib49">49</xref>].</p>
</sec>
<sec id="sec7.2">
<label>7.2</label>
<title>Intervertebral disc degeneration (IDD)</title>
<p id="p0445">One of the most common causes of lower back pain is IDD, which contributes to disability and social burden [<xref ref-type="bibr" rid="bib97">97</xref>]. Recently, IDD therapies have been mainly aimed at alleviating pain symptoms, which only give temporary advantages rather than permanent cure [<xref ref-type="bibr" rid="bib97">97</xref>]. Some factors have been attributed to the pathogenesis of IDD, including apoptosis of nucleus pulposus (NP) cells (Inner core of vertebral disc), loss of extracellular matrix and miRNAs dysfunction [<xref ref-type="bibr" rid="bib98">98</xref>]. miR-486-5p expression was found to be down-regulated and FOXO1 was up-regulated in NP cells [<xref ref-type="bibr" rid="bib62">62</xref>]. FOXO1 stimulates inflammatory cytokines and extracellular matrix degradation [<xref ref-type="bibr" rid="bib99">99</xref>]. Ectopic expression of miR-486-5p leads to FOXO1 inhibition [<xref ref-type="bibr" rid="bib99">99</xref>]. Consequently, miR-486-5p could lead to prevention of inflammatory responses, suppression of matrix degradation and apoptosis of NP Cells and thus radically alleviating IDD [<xref ref-type="bibr" rid="bib99">99</xref>].</p>
</sec>
<sec id="sec7.3">
<label>7.3</label>
<title>Coronary artery disease (CAD)</title>
<p id="p0450">Atherosclerosis is considered an inflammatory disease caused and/or worsened by lipid metabolic disorders [<xref ref-type="bibr" rid="bib100">100</xref>]. The development of atherosclerotic plaque in the coronary artery wall results in CAD [<xref ref-type="bibr" rid="bib101">101</xref>]. miR-486-5p expression was found to be highly up-regulated in CAD patients [<xref ref-type="bibr" rid="bib101">101</xref>]. Also, miR-486-5p expression was found to be elevated in a similar pattern as HDL2 [<xref ref-type="bibr" rid="bib101">101</xref>]. Thus this study suggests that measurement of miR-486-5p along with some lipid-related biomarkers might be a tool in differentiating between stable and vulnerable CAD patients [<xref ref-type="bibr" rid="bib101">101</xref>].</p>
</sec>
<sec id="sec7.4">
<label>7.4</label>
<title>Cystic fibrosis (CF)</title>
<p id="p0455">CF is a genetic disease caused by mutations in the gene of cystic fibrosis conductance regulator (CFTR) [<xref ref-type="bibr" rid="bib102">102</xref>,<xref ref-type="bibr" rid="bib103">103</xref>]. The Caucasian population's most prominent lethal genetic disease is the CF [<xref ref-type="bibr" rid="bib102">102</xref>]. A significant clinical problem remains the phenotypic heterogeneity of patients with the same CFTR genotype [<xref ref-type="bibr" rid="bib103">103</xref>,<xref ref-type="bibr" rid="bib104">104</xref>]. This has contributed to an ongoing research for new molecular drivers important to CF pathophysiology that could be an interest as biomarkers or therapeutic tools [<xref ref-type="bibr" rid="bib105">105</xref>]. High throughput microarray was used to identify Extracellular miRNAs (EC miRNAs) in plasma of CF patients to be used as diagnostic markers [<xref ref-type="bibr" rid="bib103">103</xref>]. miR-486-5p was the most deregulated EC miRNA differentially expressed in CF patients' plasma samples compared to healthy controls thus verifying its potential to act as a CF-associated biomarker [<xref ref-type="bibr" rid="bib103">103</xref>].</p>
</sec>
<sec id="sec7.5">
<label>7.5</label>
<title>Congenital heart diseases</title>
<p id="p0460">It was found that miR-486-5p is elevated in children with cyanotic as well as acyanotic heart diseases and increases the differentiation of CD34 <sup>+</sup> cells (upstream of hematopoietic differentiation) [<xref ref-type="bibr" rid="bib106">106</xref>,<xref ref-type="bibr" rid="bib107">107</xref>]. Thus, increased expression of miR-486-5p is thought to be a compensatory mechanism by raising circulating hemocytes to compensate for chronic tissue hypoxia [<xref ref-type="bibr" rid="bib106">106</xref>].</p>
</sec>
</sec>
<sec id="sec8">
<label>8</label>
<title>miR-486-3p role in non-oncological phenotypes</title>
<sec id="sec8.1">
<label>8.1</label>
<title>Heart diseases</title>
<p id="p0465">As previously described the high stability of miRNAs promotes its usage as potential diagnostic and prognostic tools in several contexts [<xref ref-type="bibr" rid="bib108">108</xref>]. miR-486-3p was reported to act as a promising biomarker in acute coronary syndrome [<xref ref-type="bibr" rid="bib109">109</xref>]. It could discriminate between patients with stable ischemic heart disease and patients with three months of ST elevated acute myocardium infarction [<xref ref-type="bibr" rid="bib110">110</xref>].</p>
</sec>
<sec id="sec8.2">
<label>8.2</label>
<title>Parkinson's disease (PD)</title>
<p id="p0470">PD mainly affects the dopamine secreting neurons. Besides, it is characterized by the presence of Lewy bodies (accumulation of abnormal alpha-synuclein) [<xref ref-type="bibr" rid="bib111">111</xref>]. miR-486-3p was found to be less expressed in PD patients, while Sirtuin 2 (SIRT2) mRNA was up-regulated in PD patients [<xref ref-type="bibr" rid="bib112">112</xref>]. Where SIRT2 is a target gene for miR-486-3p, SIRT2 elevation was reported to deteriorate the motor injury and its inhibition reduces alpha-synuclein accumulation in U87 and SH-SY5Y cells [<xref ref-type="bibr" rid="bib112">112</xref>]. Thus the overexpression of miR-486-3p inhibits SIRT2, consequently reducing alpha-synuclein induced neurotoxicity in PD [<xref ref-type="bibr" rid="bib112">112</xref>].</p>
</sec>
<sec id="sec8.3">
<label>8.3</label>
<title>Autism</title>
<p id="p0475">Autism is a neurodevelopmental disorder characterized by 3 characteristics in the Mental Disorders Diagnostic and Statistical Manual 5 (DSM-5): Loss of social communication, Limited interest, and Repetitive behavior [<xref ref-type="bibr" rid="bib113">113</xref>]. AT-rich interaction domain 1B (ARID1B) is a mutated gene that is an autism spectrum disorder, also codes a factor for chromatin remodeling [<xref ref-type="bibr" rid="bib114">114</xref>]. It was believed that miR-486-3p has an important role in autism, where miR-486-3p inhibition leads to an increase in the mRNA and protein levels of ARID1B in SH-SY5 cell line [<xref ref-type="bibr" rid="bib115">115</xref>]. Thus miR-486-3p/ARIDIB axis acts as a revolutionizing pathway alleviating a vicious circuit of behavior disorders experienced by the autistic patients [<xref ref-type="bibr" rid="bib116">116</xref>].</p>
</sec>
<sec id="sec8.4">
<label>8.4</label>
<title>Recurrent miscarriage (RM)</title>
<p id="p0480">miR-486-3p expression was found to be reduced in patients experiencing RM [<xref ref-type="bibr" rid="bib45">45</xref>]. However, in the peri-implantation period, miR-486-3p expression is significantly high directly correlated with the implantation capacity [<xref ref-type="bibr" rid="bib45">45</xref>]. Thus upon miR-486-3p repression, implantation of embryos is affected and thus RM is directly associated with miR-486-3p abnormal expression [<xref ref-type="bibr" rid="bib45">45</xref>].</p>
</sec>
<sec id="sec8.5">
<label>8.5</label>
<title>Deficiencies in fetal hemoglobin synthesis</title>
<p id="p0485">Many miRNAs have been involved in the developmental progression of globin gene expression and in the reactivation of fetal hemoglobin (HbF)-related genes [<xref ref-type="bibr" rid="bib117">117</xref>]. For adults, variable HbF levels can continue without medical consequences; more elevated HbF levels have a major impact on the incidence of certain hemoglobin disorders, such as sickle cell anemia and β-thalassemia [<xref ref-type="bibr" rid="bib118">118</xref>]. Modern genetic studies concentrated on natural variation of the level of HbF expression in the human population established BCL11A as a new regulator of hemoglobin switching developmental control and silencing expression of γ-globin in adults [<xref ref-type="bibr" rid="bib119">119</xref>]. In general, it has been stated that miR-486-3p is abundantly expressed in erythroid cells in the adult hematopoietic system, where miR-486-3p could inhibit erythroid differentiation by regulating TAL1 (SCL), a transcription factor involved in regulating erythroid-specific gene expression [<xref ref-type="bibr" rid="bib120">120</xref>]. It has been shown that miR-486-3p specifically targets BCL11A mRNA and shows that altering the expression miR-486-3p controls the levels of BCL11A protein modulating the expression of γ-globin [<xref ref-type="bibr" rid="bib120">120</xref>]. These findings show that miR-486-3p contributes to HbF control during adult erythropoiesis through post-transcriptional inhibition of BCL11A expression as summarized in <xref ref-type="fig" rid="fig4">Fig. 4</xref> [<xref ref-type="bibr" rid="bib120">120</xref>].</p>
</sec>
</sec>
<sec id="sec9">
<label>9</label>
<title>Interplay between miR-486-5p/miR-486-3p and other ncRNA molecules</title>
<p id="p0490">Recently the crosstalk between the ncRNAs has spotted the light onto the importance of investigating the upstream regulators of the upstream regulators (miRNAs) [<xref ref-type="bibr" rid="bib36">36</xref>]. Competing endogenous RNAs (ceRNAs) is a new concept of networking and complex circuit that has been drawn connecting ncRNAs with each-others. Upon the discovery of other ncRNA molecules such as lncRNAs, circRNAs, pseudoRNAs, those ncRNAs have been positioned in an upstream regulatory role to the miRNAs acting through sponging the miRNAs and consequently de-repressing the miRNAs' targets [<xref ref-type="bibr" rid="bib60">60</xref>,<xref ref-type="bibr" rid="bib121">121</xref>,<xref ref-type="bibr" rid="bib122">122</xref>]. Lately, miR-486-5p has been highlighted to play an essential part of different ceRNAs circuits. For instance, miR-486-5p has been reported to be a direct target for the oncogenic lncRNA, X-inactive specific transcript (XIST). where XIST acts as an oncogenic lncRNA in colorectal cancer cells through sponging the tumor suppressor miR-486-5p and de-repressing (or inducing) miR-486-5p pro-invasive protein target, neuopilin-2 [<xref ref-type="bibr" rid="bib60">60</xref>]. Lately it has been reported that XIST is not the solo-player in modulating miR-486-5p levels as also the lncRNA-DLGAP1-AS1 has been reported to be an oncogenic lncRNA in HCC that is able of sequestering miR-486-5p in Huh7 cells [<xref ref-type="bibr" rid="bib123">123</xref>]. On the other hand, it is important to note that our research group has recently highlighted a dominant role of miR-486-5p in trimming the oncogenic activity of the lncRNAs H19 and MALAT1 (unpublished data). Nonetheless, as reported earlier miR-486-3p could also be the prey of circRNAs. In LSCC, circFLNAs were found to act an oncogenic circRNA also through impounding miR-486-3p and suppress its anti-tumor activity [<xref ref-type="bibr" rid="bib93">93</xref>]. Collectively, those few studies highlight a clear research gap in connecting the lines between different classes of ncRNAs and the assembly of the ceRNAs circuits that when dys-regulated lead to several malignant and non-malignant phenotypes.</p>
</sec>
<sec id="sec10">
<label>10</label>
<title>Conclusion</title>
<p id="p0495">Unraveling the factors underlying the development and the progression of several deadly or life-threatening diseases such cancer, heart diseases and metabolic disorders remains a research priority for all scientists across the globe. In this review, we highlighted very important players from our point of view which are the ncRNAs. As ncRNAs have the potential to simultaneously affect the disease development, progression, aggression, metastasis in case of malignant diseases and the resistance to the conventional therapeutic approaches in several pathological conditions. miR-486-5p and miR-486-3p have been crystallized as 2 dominant players in several malignant and non-malignant conditions. miR-486-5p and miR-486-3p have been positioned in a very high rank with regards to its diagnostic and prognostic values. Yet still more studies on larger cohort of patients are needed to verify such conclusions. On the other hand, the escalating number of studies focusing on miR-486-5p and/or miR-486-3p in oncology had put them under the spotlight and promotes their therapeutic potential as promising tumor suppressor miRNAs with a positive role on the immune recognition ability and the alleviating of the immune suppressive tumor microenvironment in BC and HCC. Extensive studies are now concerned about implementing different strategies for refilling the miRNAs with tumor suppressive function such as miR-486-5p and miR-486-3p inside the tumors in cancer patients [<xref ref-type="bibr" rid="bib124">124</xref>]. Fortunately, therapeutic strategies to manipulate miRNAs have advanced from laboratory to bedside in the short time since the discovery of miRNAs, with some productive phase I trials and continuing phase II trials [<xref ref-type="bibr" rid="bib6">6</xref>]. One of the major challenges in the design of miRNA-based therapies is finding the appropriate miRNAs candidates or miRNAs targets for each type of disease. Other obstacles include developing miRNA delivery vehicles that provide the therapeutic candidate with higher stability and tissue-specific targeting, and limiting possible toxicity and off-target effects [<xref ref-type="bibr" rid="bib125">125</xref>]. But the bright side of the story is that a very recent study has proved the success of delivering anticancer miRNA-loaded pegylated poly lactic-co-glycolic acid (PLGA) nanoparticles to target regions in deep organs in large animal models [<xref ref-type="bibr" rid="bib123">123</xref>]. Therefore, this review highlights the promising role of miR-486-5p as therapeutic tools for HCC and BC in particular and hope to inspire scientists to unravel more extensive research about the role of miR-486-3p in different oncological settings to be able to have the full picture and also highlights the importance to focus on the other ceRNAs that could affect the levels and the activity of miR-486-5p and miR-486-3p in the cells.</p>
</sec>
</body>
<back>
<ref-list id="cebib0010">
<title>References</title>
<ref id="bib1">
<label>1</label>
<element-citation id="sref1" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delihas</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Discovery and characterization of the first non-coding RNA that regulates gene expression, micF RNA: a historical perspective</article-title>
<source/>World J. Biol. Chem.
          <volume>6</volume>
<issue>4</issue>
<year>2015</year>
<fpage>272</fpage>
<lpage>280</lpage>
<pub-id pub-id-type="pmid">26629310</pub-id>
</element-citation>
</ref>
<ref id="bib2">
<label>2</label>
<element-citation id="sref2" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anastasiadou</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Jacob</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>Non-coding RNA networks in cancer</article-title>
<source/>Nat. Rev. Cancer
          <volume>18</volume>
<issue>1</issue>
<year>2018</year>
<fpage>5</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="pmid">29170536</pub-id>
</element-citation>
</ref>
<ref id="bib3">
<label>3</label>
<element-citation id="sref3" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mizuno</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Inouye</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>A unique mechanism regulating gene expression: translational inhibition by a complementary RNA transcript (micRNA)</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>81</volume>
<issue>7</issue>
<year>1984</year>
<fpage>1966</fpage>
<lpage>1970</lpage>
<pub-id pub-id-type="pmid">6201848</pub-id>
</element-citation>
</ref>
<ref id="bib4">
<label>4</label>
<element-citation id="sref4" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waters</surname>
<given-names>L.S.</given-names>
</name>
<name>
<surname>Storz</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>Regulatory RNAs in bacteria</article-title>
<source/>Cell
          <volume>136</volume>
<issue>4</issue>
<year>2009</year>
<fpage>615</fpage>
<lpage>628</lpage>
<pub-id pub-id-type="pmid">19239884</pub-id>
</element-citation>
</ref>
<ref id="bib5">
<label>5</label>
<element-citation id="sref5" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Brien</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Overview of MicroRNA biogenesis, mechanisms of actions, and circulation</article-title>
<source/>Front. Endocrinol.
          <volume>9</volume>
<year>2018</year>
<fpage>402</fpage>
</element-citation>
</ref>
<ref id="bib6">
<label>6</label>
<element-citation id="sref6" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rupaimoole</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Slack</surname>
<given-names>F.J.</given-names>
</name>
</person-group>
<article-title>MicroRNA therapeutics: towards a new era for the management of cancer and other diseases</article-title>
<source/>Nat. Rev. Drug Discov.
          <volume>16</volume>
<issue>3</issue>
<year>2017</year>
<fpage>203</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="pmid">28209991</pub-id>
</element-citation>
</ref>
<ref id="bib7">
<label>7</label>
<element-citation id="sref7" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Losko</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kotlinowski</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jura</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNAs in metabolic syndrome related disorders</article-title>
<source/>Mediat. Inflamm.
          <volume>2016</volume>
<year>2016</year>
<fpage>5365209</fpage>
</element-citation>
</ref>
<ref id="bib8">
<label>8</label>
<element-citation id="sref8" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zampetaki</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Albrecht</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Steinhofel</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA structure and function: is there a link?</article-title>
<source/>Front. Physiol.
          <volume>9</volume>
<year>2018</year>
<fpage>1201</fpage>
<pub-id pub-id-type="pmid">30197605</pub-id>
</element-citation>
</ref>
<ref id="bib9">
<label>9</label>
<element-citation id="sref9" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>L.L.</given-names>
</name>
<name>
<surname>Carmichael</surname>
<given-names>G.G.</given-names>
</name>
</person-group>
<article-title>Decoding the function of nuclear long non-coding RNAs</article-title>
<source/>Curr. Opin. Cell Biol.
          <volume>22</volume>
<issue>3</issue>
<year>2010</year>
<fpage>357</fpage>
<lpage>364</lpage>
<pub-id pub-id-type="pmid">20356723</pub-id>
</element-citation>
</ref>
<ref id="bib10">
<label>10</label>
<element-citation id="sref10" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bolha</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ravnik-Glavac</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Glavac</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Circular RNAs: biogenesis, function, and a role as possible cancer biomarkers</article-title>
<source/>Int J Genomics
          <volume>2017</volume>
<year>2017</year>
<fpage>6218353</fpage>
<pub-id pub-id-type="pmid">29349062</pub-id>
</element-citation>
</ref>
<ref id="bib11">
<label>11</label>
<element-citation id="sref11" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ling</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fabbri</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Calin</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>MicroRNAs and other non-coding RNAs as targets for anticancer drug development</article-title>
<source/>Nat. Rev. Drug Discov.
          <volume>12</volume>
<issue>11</issue>
<year>2013</year>
<fpage>847</fpage>
<lpage>865</lpage>
<pub-id pub-id-type="pmid">24172333</pub-id>
</element-citation>
</ref>
<ref id="bib12">
<label>12</label>
<element-citation id="sref12" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>MicroRNAs from plants to animals, do they define a new messenger for communication?</article-title>
<source/>Nutr. Metab.
          <volume>15</volume>
<year>2018</year>
<fpage>68</fpage>
</element-citation>
</ref>
<ref id="bib13">
<label>13</label>
<element-citation id="sref13" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Skalsky</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Cullen</surname>
<given-names>B.R.</given-names>
</name>
</person-group>
<article-title>Viruses, microRNAs, and host interactions</article-title>
<source/>Annu. Rev. Microbiol.
          <volume>64</volume>
<year>2010</year>
<fpage>123</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="pmid">20477536</pub-id>
</element-citation>
</ref>
<ref id="bib14">
<label>14</label>
<element-citation id="sref14" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hombach</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kretz</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Non-coding RNAs: classification, biology and functioning</article-title>
<source/>Adv. Exp. Med. Biol.
          <volume>937</volume>
<year>2016</year>
<fpage>3</fpage>
<lpage>17</lpage>
<pub-id pub-id-type="pmid">27573892</pub-id>
</element-citation>
</ref>
<ref id="bib15">
<label>15</label>
<element-citation id="sref15" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hayder</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>MicroRNAs: crucial regulators of placental development</article-title>
<source/>Reproduction
          <volume>155</volume>
<issue>6</issue>
<year>2018</year>
<fpage>R259</fpage>
<lpage>R271</lpage>
<pub-id pub-id-type="pmid">29615475</pub-id>
</element-citation>
</ref>
<ref id="bib16">
<label>16</label>
<element-citation id="sref16" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>E.N.</given-names>
</name>
</person-group>
<article-title>MicroRNA regulatory networks in cardiovascular development</article-title>
<source/>Dev. Cell
          <volume>18</volume>
<issue>4</issue>
<year>2010</year>
<fpage>510</fpage>
<lpage>525</lpage>
<pub-id pub-id-type="pmid">20412767</pub-id>
</element-citation>
</ref>
<ref id="bib17">
<label>17</label>
<element-citation id="sref17" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Issler</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Determining the role of microRNAs in psychiatric disorders</article-title>
<source/>Nat. Rev. Neurosci.
          <volume>16</volume>
<issue>4</issue>
<year>2015</year>
<fpage>201</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="pmid">25790865</pub-id>
</element-citation>
</ref>
<ref id="bib18">
<label>18</label>
<element-citation id="sref18" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ha</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>V.N.</given-names>
</name>
</person-group>
<article-title>Regulation of microRNA biogenesis</article-title>
<source/>Nat. Rev. Mol. Cell Biol.
          <volume>15</volume>
<issue>8</issue>
<year>2014</year>
<fpage>509</fpage>
<lpage>524</lpage>
<pub-id pub-id-type="pmid">25027649</pub-id>
</element-citation>
</ref>
<ref id="bib19">
<label>19</label>
<element-citation id="sref19" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanzer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Stadler</surname>
<given-names>P.F.</given-names>
</name>
</person-group>
<article-title>Molecular evolution of a microRNA cluster</article-title>
<source/>J. Mol. Biol.
          <volume>339</volume>
<issue>2</issue>
<year>2004</year>
<fpage>327</fpage>
<lpage>335</lpage>
<pub-id pub-id-type="pmid">15136036</pub-id>
</element-citation>
</ref>
<ref id="bib20">
<label>20</label>
<element-citation id="sref20" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abd El-Maqsoud</surname>
<given-names>N.M.</given-names>
</name>
</person-group>
<article-title>Golgi phosphoprotein-3 and Y-Box-Binding protein-1 are novel markers correlating with poor prognosis in prostate cancer</article-title>
<source/>Clin. Genitourin. Cancer
          <volume>14</volume>
<issue>2</issue>
<year>2016</year>
<fpage>e143</fpage>
<lpage>e152</lpage>
<pub-id pub-id-type="pmid">26794392</pub-id>
</element-citation>
</ref>
<ref id="bib21">
<label>21</label>
<element-citation id="sref21" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alarcon</surname>
<given-names>C.R.</given-names>
</name>
</person-group>
<article-title>N6-methyladenosine marks primary microRNAs for processing</article-title>
<source/>Nature
          <volume>519</volume>
<issue>7544</issue>
<year>2015</year>
<fpage>482</fpage>
<lpage>485</lpage>
<pub-id pub-id-type="pmid">25799998</pub-id>
</element-citation>
</ref>
<ref id="bib22">
<label>22</label>
<element-citation id="sref22" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khvorova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Jayasena</surname>
<given-names>S.D.</given-names>
</name>
</person-group>
<article-title>Functional siRNAs and miRNAs exhibit strand bias</article-title>
<source/>Cell
          <volume>115</volume>
<issue>2</issue>
<year>2003</year>
<fpage>209</fpage>
<lpage>216</lpage>
<pub-id pub-id-type="pmid">14567918</pub-id>
</element-citation>
</ref>
<ref id="bib23">
<label>23</label>
<element-citation id="sref23" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>J.S.</given-names>
</name>
</person-group>
<article-title>Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>107</volume>
<issue>34</issue>
<year>2010</year>
<fpage>15163</fpage>
<lpage>15168</lpage>
<pub-id pub-id-type="pmid">20699384</pub-id>
</element-citation>
</ref>
<ref id="bib24">
<label>24</label>
<element-citation id="sref24" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheloufi</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>A dicer-independent miRNA biogenesis pathway that requires Ago catalysis</article-title>
<source/>Nature
          <volume>465</volume>
<issue>7298</issue>
<year>2010</year>
<fpage>584</fpage>
<lpage>589</lpage>
<pub-id pub-id-type="pmid">20424607</pub-id>
</element-citation>
</ref>
<ref id="bib25">
<label>25</label>
<element-citation id="sref25" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carthew</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Sontheimer</surname>
<given-names>E.J.</given-names>
</name>
</person-group>
<article-title>Origins and Mechanisms of miRNAs and siRNAs</article-title>
<source/>Cell
          <volume>136</volume>
<issue>4</issue>
<year>2009</year>
<fpage>642</fpage>
<lpage>655</lpage>
<pub-id pub-id-type="pmid">19239886</pub-id>
</element-citation>
</ref>
<ref id="bib26">
<label>26</label>
<element-citation id="sref26" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pisarello</surname>
<given-names>M.J.</given-names>
</name>
</person-group>
<article-title>MicroRNAs in the cholangiopathies: pathogenesis, diagnosis, and treatment</article-title>
<source/>J. Clin. Med.
          <volume>4</volume>
<issue>9</issue>
<year>2015</year>
<fpage>1688</fpage>
<lpage>1712</lpage>
<pub-id pub-id-type="pmid">26343736</pub-id>
</element-citation>
</ref>
<ref id="bib27">
<label>27</label>
<element-citation id="sref27" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iorio</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Croce</surname>
<given-names>C.M.</given-names>
</name>
</person-group>
<article-title>microRNA involvement in human cancer</article-title>
<source/>Carcinogenesis
          <volume>33</volume>
<issue>6</issue>
<year>2012</year>
<fpage>1126</fpage>
<lpage>1133</lpage>
<pub-id pub-id-type="pmid">22491715</pub-id>
</element-citation>
</ref>
<ref id="bib28">
<label>28</label>
<element-citation id="sref28" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shenouda</surname>
<given-names>S.K.</given-names>
</name>
<name>
<surname>Alahari</surname>
<given-names>S.K.</given-names>
</name>
</person-group>
<article-title>MicroRNA function in cancer: oncogene or a tumor suppressor?</article-title>
<source/>Cancer Metastasis Rev.
          <volume>28</volume>
<issue>3–4</issue>
<year>2009</year>
<fpage>369</fpage>
<lpage>378</lpage>
<pub-id pub-id-type="pmid">20012925</pub-id>
</element-citation>
</ref>
<ref id="bib29">
<label>29</label>
<element-citation id="sref29" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dharap</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>MicroRNA miR-324-3p induces promoter-mediated expression of RelA gene</article-title>
<source/>PLoS One
          <volume>8</volume>
<issue>11</issue>
<year>2013</year>
<object-id pub-id-type="publisher-id">e79467</object-id>
</element-citation>
</ref>
<ref id="bib30">
<label>30</label>
<element-citation id="sref30" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillai</surname>
<given-names>R.S.</given-names>
</name>
</person-group>
<article-title>MicroRNA function: multiple mechanisms for a tiny RNA?</article-title>
<source/>RNA
          <volume>11</volume>
<issue>12</issue>
<year>2005</year>
<fpage>1753</fpage>
<lpage>1761</lpage>
<pub-id pub-id-type="pmid">16314451</pub-id>
</element-citation>
</ref>
<ref id="bib31">
<label>31</label>
<element-citation id="sref31" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jo</surname>
<given-names>M.H.</given-names>
</name>
</person-group>
<article-title>Human Argonaute 2 has diverse reaction pathways on target RNAs</article-title>
<source/>Mol. Cell
          <volume>59</volume>
<issue>1</issue>
<year>2015</year>
<fpage>117</fpage>
<lpage>124</lpage>
<pub-id pub-id-type="pmid">26140367</pub-id>
</element-citation>
</ref>
<ref id="bib32">
<label>32</label>
<element-citation id="sref32" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vasudevan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Steitz</surname>
<given-names>J.A.</given-names>
</name>
</person-group>
<article-title>AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2</article-title>
<source/>Cell
          <volume>128</volume>
<issue>6</issue>
<year>2007</year>
<fpage>1105</fpage>
<lpage>1118</lpage>
<pub-id pub-id-type="pmid">17382880</pub-id>
</element-citation>
</ref>
<ref id="bib33">
<label>33</label>
<element-citation id="sref33" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youness</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression</article-title>
<source/>Growth Factors
          <volume>34</volume>
<issue>3–4</issue>
<year>2016</year>
<fpage>128</fpage>
<lpage>140</lpage>
<pub-id pub-id-type="pmid">27388576</pub-id>
</element-citation>
</ref>
<ref id="bib34">
<label>34</label>
<element-citation id="sref34" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youness</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc</article-title>
<source/>Oncol Lett
          <volume>12</volume>
<issue>4</issue>
<year>2016</year>
<fpage>2567</fpage>
<lpage>2573</lpage>
<pub-id pub-id-type="pmid">27698829</pub-id>
</element-citation>
</ref>
<ref id="bib35">
<label>35</label>
<element-citation id="sref35" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Truesdell</surname>
<given-names>S.S.</given-names>
</name>
</person-group>
<article-title>MicroRNA-mediated mRNA translation activation in quiescent cells and oocytes involves recruitment of a nuclear microRNP</article-title>
<source/>Sci. Rep.
          <volume>2</volume>
<year>2012</year>
<fpage>842</fpage>
<pub-id pub-id-type="pmid">23150790</pub-id>
</element-citation>
</ref>
<ref id="bib36">
<label>36</label>
<element-citation id="sref36" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youness</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Gad</surname>
<given-names>M.Z.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNAs: functional regulatory players in breast cancer</article-title>
<source/>Noncoding RNA Res
          <volume>4</volume>
<issue>1</issue>
<year>2019</year>
<fpage>36</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="pmid">30891536</pub-id>
</element-citation>
</ref>
<ref id="bib37">
<label>37</label>
<element-citation id="sref37" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Cancer statistics</article-title>
<comment>2009</comment>
<source/>CA A Cancer J. Clin.
          <volume>59</volume>
<issue>4</issue>
<year>2009</year>
<fpage>225</fpage>
<lpage>249</lpage>
</element-citation>
</ref>
<ref id="bib38">
<label>38</label>
<element-citation id="sref38" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youness</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>A methoxylated quercetin glycoside harnesses HCC tumor progression in a TP53/miR-15/miR-16 dependent manner</article-title>
<source/>Nat. Prod. Res.
          <year>2018</year>
<fpage>1</fpage>
<lpage>6</lpage>
</element-citation>
</ref>
<ref id="bib39">
<label>39</label>
<element-citation id="sref39" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shaalan</surname>
<given-names>Y.M.</given-names>
</name>
</person-group>
<article-title>Destabilizing the interplay between miR-1275 and IGF2BPs by Tamarix articulata and quercetin in hepatocellular carcinoma</article-title>
<source/>Nat. Prod. Res.
          <volume>32</volume>
<issue>18</issue>
<year>2018</year>
<fpage>2217</fpage>
<lpage>2220</lpage>
<pub-id pub-id-type="pmid">28817968</pub-id>
</element-citation>
</ref>
<ref id="bib40">
<label>40</label>
<element-citation id="sref40" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rahmoon</surname>
<given-names>M.A.</given-names>
</name>
</person-group>
<article-title>MiR-615-5p depresses natural killer cells cytotoxicity through repressing IGF-1R in hepatocellular carcinoma patients</article-title>
<source/>Growth Factors
          <volume>35</volume>
<issue>2–3</issue>
<year>2017</year>
<fpage>76</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">28747084</pub-id>
</element-citation>
</ref>
<ref id="bib41">
<label>41</label>
<element-citation id="sref41" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Youness</surname>
<given-names>R.A.</given-names>
</name>
</person-group>
<article-title>A novel role of sONE/NOS3/NO signaling cascade in mediating hydrogen sulphide bilateral effects on triple negative breast cancer progression</article-title>
<source/>Nitric Oxide
          <volume>80</volume>
<year>2018</year>
<fpage>12</fpage>
<lpage>23</lpage>
<pub-id pub-id-type="pmid">30081213</pub-id>
</element-citation>
</ref>
<ref id="bib42">
<label>42</label>
<element-citation id="sref42" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Awad</surname>
<given-names>A.R.</given-names>
</name>
</person-group>
<article-title>An acetylated derivative of vitexin halts MDA-MB-231 cellular progression and improves its immunogenic profile through tuning miR- 20a-MICA/B axis</article-title>
<source/>Nat. Prod. Res.
          <year>2019</year>
<fpage>1</fpage>
<lpage>5</lpage>
</element-citation>
</ref>
<ref id="bib43">
<label>43</label>
<element-citation id="sref43" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calin</surname>
<given-names>G.A.</given-names>
</name>
</person-group>
<article-title>Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia</article-title>
<source/>Proc. Natl. Acad. Sci. U. S. A.
          <volume>99</volume>
<issue>24</issue>
<year>2002</year>
<fpage>15524</fpage>
<lpage>15529</lpage>
<pub-id pub-id-type="pmid">12434020</pub-id>
</element-citation>
</ref>
<ref id="bib44">
<label>44</label>
<element-citation id="sref44" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>MiR-486 as an effective biomarker in cancer diagnosis and prognosis: a systematic review and meta-analysis</article-title>
<source/>Oncotarget
          <volume>9</volume>
<issue>17</issue>
<year>2018</year>
<fpage>13948</fpage>
<lpage>13958</lpage>
<pub-id pub-id-type="pmid">29568407</pub-id>
</element-citation>
</ref>
<ref id="bib45">
<label>45</label>
<element-citation id="sref45" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gu</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Aberrant placental villus expression of miR-486-3p and miR-3074-5p in recurrent miscarriage patients and uterine expression of these MicroRNAs during early pregnancy in mice</article-title>
<source/>Gynecol. Obstet. Investig.
          <year>2015</year>
</element-citation>
</ref>
<ref id="bib46">
<label>46</label>
<element-citation id="sref46" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA DLGAP1-AS1 promotes cell proliferation in hepatocellular carcinoma via sequestering miR-486-5p</article-title>
<source/>J. Cell. Biochem.
          <year>2019</year>
</element-citation>
</ref>
<ref id="bib47">
<label>47</label>
<element-citation id="sref47" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>Role of miR-486-5p in regulating renal cell carcinoma cell proliferation and apoptosis via TGF-beta-activated kinase 1</article-title>
<source/>J. Cell. Biochem.
          <volume>120</volume>
<issue>3</issue>
<year>2019</year>
<fpage>2954</fpage>
<lpage>2963</lpage>
<pub-id pub-id-type="pmid">30537206</pub-id>
</element-citation>
</ref>
<ref id="bib48">
<label>48</label>
<element-citation id="sref48" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Serum miR-486-5p as a diagnostic marker in cervical cancer: with investigation of potential mechanisms</article-title>
<source/>BMC Canc.
          <volume>18</volume>
<issue>1</issue>
<year>2018</year>
<fpage>61</fpage>
</element-citation>
</ref>
<ref id="bib49">
<label>49</label>
<element-citation id="sref49" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bakr Zaki</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Potential role of circulating microRNAs (486-5p, 497, 509-5p and 605) in metabolic syndrome Egyptian male patients</article-title>
<source/>Diabetes Metab Syndr Obes
          <volume>12</volume>
<year>2019</year>
<fpage>601</fpage>
<lpage>611</lpage>
<pub-id pub-id-type="pmid">31190928</pub-id>
</element-citation>
</ref>
<ref id="bib50">
<label>50</label>
<element-citation id="sref50" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zappa</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Mousa</surname>
<given-names>S.A.</given-names>
</name>
</person-group>
<article-title>Non-small cell lung cancer: current treatment and future advances</article-title>
<source/>Transl. Lung Cancer Res.
          <volume>5</volume>
<issue>3</issue>
<year>2016</year>
<fpage>288</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">27413711</pub-id>
</element-citation>
</ref>
<ref id="bib51">
<label>51</label>
<element-citation id="sref51" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jin</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486-5p improves nonsmall-cell lung cancer chemotherapy sensitivity and inhibits epithelial-mesenchymal transition by targeting twinfilin actin binding protein 1</article-title>
<source/>J. Int. Med. Res.
          <year>2019</year>
<comment>300060519850739</comment>
</element-citation>
</ref>
<ref id="bib52">
<label>52</label>
<element-citation id="sref52" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kumar</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Negative regulation of the tumor suppressor p53 gene by microRNAs</article-title>
<source/>Oncogene
          <volume>30</volume>
<issue>7</issue>
<year>2011</year>
<fpage>843</fpage>
<lpage>853</lpage>
<pub-id pub-id-type="pmid">20935678</pub-id>
</element-citation>
</ref>
<ref id="bib53">
<label>53</label>
<element-citation id="sref53" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Negative regulation of tumor suppressor p53 by microRNA miR-504</article-title>
<source/>Mol. Cell
          <volume>38</volume>
<issue>5</issue>
<year>2010</year>
<fpage>689</fpage>
<lpage>699</lpage>
<pub-id pub-id-type="pmid">20542001</pub-id>
</element-citation>
</ref>
<ref id="bib54">
<label>54</label>
<element-citation id="sref54" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Expression of miR-486-5p and its signi fi cance in lung squamous cell carcinoma</article-title>
<source/>J. Cell. Biochem.
          <volume>120</volume>
<issue>8</issue>
<year>2019</year>
<fpage>13912</fpage>
<lpage>13923</lpage>
<pub-id pub-id-type="pmid">30963622</pub-id>
</element-citation>
</ref>
<ref id="bib55">
<label>55</label>
<element-citation id="sref55" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Colorectal cancer characterization and therapeutic target prediction based on microRNA expression profile</article-title>
<source/>Sci. Rep.
          <volume>6</volume>
<year>2016</year>
<fpage>20616</fpage>
<pub-id pub-id-type="pmid">26852921</pub-id>
</element-citation>
</ref>
<ref id="bib56">
<label>56</label>
<element-citation id="sref56" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/beta-catenin signal pathways</article-title>
<source/>Cell Death Dis.
          <volume>9</volume>
<issue>10</issue>
<year>2018</year>
<fpage>1037</fpage>
<pub-id pub-id-type="pmid">30305607</pub-id>
</element-citation>
</ref>
<ref id="bib57">
<label>57</label>
<element-citation id="sref57" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bjornetro</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>An experimental strategy unveiling exosomal microRNAs 486-5p, 181a-5p and 30d-5p from hypoxic tumour cells as circulating indicators of high-risk rectal cancer</article-title>
<source/>J. Extracell. Vesicles
          <volume>8</volume>
<issue>1</issue>
<year>2019</year>
<fpage>1567219</fpage>
<pub-id pub-id-type="pmid">30728923</pub-id>
</element-citation>
</ref>
<ref id="bib58">
<label>58</label>
<element-citation id="sref58" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tovar-Camargo</surname>
<given-names>O.A.</given-names>
</name>
<name>
<surname>Toden</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Goel</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Exosomal microRNA biomarkers: emerging frontiers in colorectal and other human cancers</article-title>
<source/>Expert Rev. Mol. Diagn
          <volume>16</volume>
<issue>5</issue>
<year>2016</year>
<fpage>553</fpage>
<lpage>567</lpage>
<pub-id pub-id-type="pmid">26892862</pub-id>
</element-citation>
</ref>
<ref id="bib59">
<label>59</label>
<element-citation id="sref59" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hon</surname>
<given-names>K.W.</given-names>
</name>
</person-group>
<article-title>Exosomes as potential biomarkers and targeted therapy in colorectal cancer: a mini-review</article-title>
<source/>Front. Pharmacol.
          <volume>8</volume>
<year>2017</year>
<fpage>583</fpage>
<pub-id pub-id-type="pmid">28894420</pub-id>
</element-citation>
</ref>
<ref id="bib60">
<label>60</label>
<element-citation id="sref60" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>LncRNA XIST facilitates proliferation and epithelial-mesenchymal transition of colorectal cancer cells through targeting miR-486-5p and promoting neuropilin-2</article-title>
<source/>J. Cell. Physiol.
          <volume>234</volume>
<issue>8</issue>
<year>2019</year>
<fpage>13747</fpage>
<lpage>13761</lpage>
<pub-id pub-id-type="pmid">30656681</pub-id>
</element-citation>
</ref>
<ref id="bib61">
<label>61</label>
<element-citation id="sref61" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells</article-title>
<source/>Tumour Biol
          <volume>35</volume>
<issue>11</issue>
<year>2014</year>
<fpage>11137</fpage>
<lpage>11145</lpage>
<pub-id pub-id-type="pmid">25104088</pub-id>
</element-citation>
</ref>
<ref id="bib62">
<label>62</label>
<element-citation id="sref62" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rask</surname>
<given-names>L.</given-names>
</name>
</person-group>
<article-title>Differential expression of miR-139, miR-486 and miR-21 in breast cancer patients sub-classified according to lymph node status</article-title>
<source/>Cell. Oncol.
          <volume>37</volume>
<issue>3</issue>
<year>2014</year>
<fpage>215</fpage>
<lpage>227</lpage>
</element-citation>
</ref>
<ref id="bib63">
<label>63</label>
<element-citation id="sref63" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>MiR-486-5p inhibits IL-22-induced epithelial-mesenchymal transition of breast cancer cell by repressing Dock1</article-title>
<source/>J. Cancer
          <volume>10</volume>
<issue>19</issue>
<year>2019</year>
<fpage>4695</fpage>
<lpage>4706</lpage>
<pub-id pub-id-type="pmid">31528235</pub-id>
</element-citation>
</ref>
<ref id="bib64">
<label>64</label>
<element-citation id="sref64" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balogh</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Hepatocellular carcinoma: a review</article-title>
<source/>J. Hepatocell. Carcinoma
          <volume>3</volume>
<year>2016</year>
<fpage>41</fpage>
<lpage>53</lpage>
<pub-id pub-id-type="pmid">27785449</pub-id>
</element-citation>
</ref>
<ref id="bib65">
<label>65</label>
<element-citation id="sref65" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors</article-title>
<source/>J. Clin. Investig.
          <volume>120</volume>
<issue>4</issue>
<year>2010</year>
<fpage>1298</fpage>
<lpage>1309</lpage>
<pub-id pub-id-type="pmid">20237410</pub-id>
</element-citation>
</ref>
<ref id="bib66">
<label>66</label>
<element-citation id="sref66" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>D.Y.</given-names>
</name>
<name>
<surname>Uzzo</surname>
<given-names>R.G.</given-names>
</name>
</person-group>
<article-title>Optimal management of localized renal cell carcinoma: surgery, ablation, or active surveillance</article-title>
<source/>J. Natl. Compr. Cancer Netw.
          <volume>7</volume>
<issue>6</issue>
<year>2009</year>
<fpage>635</fpage>
<lpage>642</lpage>
<comment>quiz 643</comment>
</element-citation>
</ref>
<ref id="bib67">
<label>67</label>
<element-citation id="sref67" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jedeszko</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib</article-title>
<source/>Sci. Transl. Med.
          <volume>7</volume>
<issue>282</issue>
<year>2015</year>
<fpage>282ra50</fpage>
</element-citation>
</ref>
<ref id="bib68">
<label>68</label>
<element-citation id="sref68" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zarrabi</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy</article-title>
<source/>J. Hematol. Oncol.
          <volume>10</volume>
<issue>1</issue>
<year>2017</year>
<fpage>38</fpage>
<pub-id pub-id-type="pmid">28153029</pub-id>
</element-citation>
</ref>
<ref id="bib69">
<label>69</label>
<element-citation id="sref69" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Expression and prognostic value of miR-486-5p in patients with gastric adenocarcinoma</article-title>
<source/>PLoS One
          <volume>10</volume>
<issue>3</issue>
<year>2015</year>
<object-id pub-id-type="publisher-id">e0119384</object-id>
</element-citation>
</ref>
<ref id="bib70">
<label>70</label>
<element-citation id="sref70" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X.P.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486-5p, which is downregulated in hepatocellular carcinoma, suppresses tumor growth by targeting PIK3R1</article-title>
<source/>FEBS J.
          <volume>282</volume>
<issue>3</issue>
<year>2015</year>
<fpage>579</fpage>
<lpage>594</lpage>
<pub-id pub-id-type="pmid">25475121</pub-id>
</element-citation>
</ref>
<ref id="bib71">
<label>71</label>
<element-citation id="sref71" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fransson</surname>
<given-names>S.</given-names>
</name>
</person-group>
<article-title>Stage-dependent expression of PI3K/Aktpathway genes in neuroblastoma</article-title>
<source/>Int. J. Oncol.
          <volume>42</volume>
<issue>2</issue>
<year>2013</year>
<fpage>609</fpage>
<lpage>616</lpage>
<pub-id pub-id-type="pmid">23232578</pub-id>
</element-citation>
</ref>
<ref id="bib72">
<label>72</label>
<element-citation id="sref72" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells</article-title>
<source/>BMC Canc.
          <volume>15</volume>
<year>2015</year>
<fpage>333</fpage>
</element-citation>
</ref>
<ref id="bib73">
<label>73</label>
<element-citation id="sref73" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Siegel</surname>
<given-names>R.</given-names>
</name>
</person-group>
<article-title>Cancer statistics, 2014</article-title>
<source/>CA A Cancer J. Clin.
          <volume>64</volume>
<issue>1</issue>
<year>2014</year>
<fpage>9</fpage>
<lpage>29</lpage>
</element-citation>
</ref>
<ref id="bib74">
<label>74</label>
<element-citation id="sref74" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiao</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>KIAA1199, a target of MicoRNA-486-5p, promotes papillary thyroid cancer invasion by influencing epithelial-mesenchymal transition (EMT)</article-title>
<source/>Med. Sci. Monit.
          <volume>25</volume>
<year>2019</year>
<fpage>6788</fpage>
<lpage>6796</lpage>
<pub-id pub-id-type="pmid">31501407</pub-id>
</element-citation>
</ref>
<ref id="bib75">
<label>75</label>
<element-citation id="sref75" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>miR-486-5p inhibits cell growth of papillary thyroid carcinoma by targeting fibrillin-1</article-title>
<source/>Biomed. Pharmacother.
          <volume>80</volume>
<year>2016</year>
<fpage>220</fpage>
<lpage>226</lpage>
<pub-id pub-id-type="pmid">27133060</pub-id>
</element-citation>
</ref>
<ref id="bib76">
<label>76</label>
<element-citation id="sref76" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer</article-title>
<source/>Oncotarget
          <volume>7</volume>
<issue>9</issue>
<year>2016</year>
<fpage>10594</fpage>
<lpage>10605</lpage>
<pub-id pub-id-type="pmid">26871282</pub-id>
</element-citation>
</ref>
<ref id="bib77">
<label>77</label>
<element-citation id="sref77" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duan</surname>
<given-names>C.</given-names>
</name>
</person-group>
<article-title>Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma</article-title>
<source/>J. Cell Mol. Med.
          <volume>18</volume>
<issue>5</issue>
<year>2014</year>
<fpage>863</fpage>
<lpage>874</lpage>
<pub-id pub-id-type="pmid">24495253</pub-id>
</element-citation>
</ref>
<ref id="bib78">
<label>78</label>
<element-citation id="sref78" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lightfoot</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Aetiology of childhood leukemia</article-title>
<source/>Bioelectromagnetics
          <issue>Suppl 7</issue>
<year>2005</year>
<fpage>S5</fpage>
<lpage>S11</lpage>
<pub-id pub-id-type="pmid">16059922</pub-id>
</element-citation>
</ref>
<ref id="bib79">
<label>79</label>
<element-citation id="sref79" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>Long non-coding RNA: a new player in cancer</article-title>
<source/>J. Hematol. Oncol.
          <volume>6</volume>
<year>2013</year>
<fpage>37</fpage>
<pub-id pub-id-type="pmid">23725405</pub-id>
</element-citation>
</ref>
<ref id="bib80">
<label>80</label>
<element-citation id="sref80" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassan</surname>
<given-names>O.</given-names>
</name>
</person-group>
<article-title>Recent updates on the role of microRNAs in prostate cancer</article-title>
<source/>J. Hematol. Oncol.
          <volume>5</volume>
<year>2012</year>
<fpage>9</fpage>
<pub-id pub-id-type="pmid">22417299</pub-id>
</element-citation>
</ref>
<ref id="bib81">
<label>81</label>
<element-citation id="sref81" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>MiR-486-5p inhibits the proliferation of leukemia cells and induces apoptosis through targeting FOXO1</article-title>
<source/>Mol. Cell. Probes
          <volume>44</volume>
<year>2019</year>
<fpage>37</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="pmid">30731134</pub-id>
</element-citation>
</ref>
<ref id="bib82">
<label>82</label>
<element-citation id="sref82" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakamura</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sakamoto</surname>
<given-names>K.</given-names>
</name>
</person-group>
<article-title>Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis</article-title>
<source/>Mol. Cell. Endocrinol.
          <volume>281</volume>
<issue>1–2</issue>
<year>2008</year>
<fpage>47</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="pmid">18035477</pub-id>
</element-citation>
</ref>
<ref id="bib83">
<label>83</label>
<element-citation id="sref83" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>The miR-486-5p plays a causative role in prostate cancer through negative regulation of multiple tumor suppressor pathways</article-title>
<source/>Oncotarget
          <volume>8</volume>
<issue>42</issue>
<year>2017</year>
<fpage>72835</fpage>
<lpage>72846</lpage>
<pub-id pub-id-type="pmid">29069829</pub-id>
</element-citation>
</ref>
<ref id="bib84">
<label>84</label>
<element-citation id="sref84" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Global cancer statistics</article-title>
<source/>CA A Cancer J. Clin.
          <volume>61</volume>
<issue>2</issue>
<year>2011</year>
<fpage>69</fpage>
<lpage>90</lpage>
</element-citation>
</ref>
<ref id="bib85">
<label>85</label>
<element-citation id="sref85" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shiu</surname>
<given-names>M.N.</given-names>
</name>
</person-group>
<article-title>Risk factors for leukoplakia and malignant transformation to oral carcinoma: a leukoplakia cohort in Taiwan</article-title>
<source/>Br. J. Canc.
          <volume>82</volume>
<issue>11</issue>
<year>2000</year>
<fpage>1871</fpage>
<lpage>1874</lpage>
</element-citation>
</ref>
<ref id="bib86">
<label>86</label>
<element-citation id="sref86" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chou</surname>
<given-names>S.T.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486-3p functions as a tumor suppressor in oral cancer by targeting DDR1</article-title>
<source/>J. Exp. Clin. Cancer Res.
          <volume>38</volume>
<issue>1</issue>
<year>2019</year>
<fpage>281</fpage>
<pub-id pub-id-type="pmid">31253192</pub-id>
</element-citation>
</ref>
<ref id="bib87">
<label>87</label>
<element-citation id="sref87" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torre</surname>
<given-names>L.A.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R.L.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>Lung cancer statistics</article-title>
<source/>Adv. Exp. Med. Biol.
          <volume>893</volume>
<year>2016</year>
<fpage>1</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="pmid">26667336</pub-id>
</element-citation>
</ref>
<ref id="bib88">
<label>88</label>
<element-citation id="sref88" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Thrombospondin enhances RANKL-dependent osteoclastogenesis and facilitates lung cancer bone metastasis</article-title>
<source/>Biochem. Pharmacol.
          <volume>166</volume>
<year>2019</year>
<fpage>23</fpage>
<lpage>32</lpage>
<pub-id pub-id-type="pmid">31075265</pub-id>
</element-citation>
</ref>
<ref id="bib89">
<label>89</label>
<element-citation id="sref89" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Torre</surname>
<given-names>L.A.</given-names>
</name>
</person-group>
<article-title>Global cancer incidence and mortality rates and trends--an update</article-title>
<source/>Cancer Epidemiol. Biomark. Prev.
          <volume>25</volume>
<issue>1</issue>
<year>2016</year>
<fpage>16</fpage>
<lpage>27</lpage>
</element-citation>
</ref>
<ref id="bib90">
<label>90</label>
<element-citation id="sref90" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ye</surname>
<given-names>H.</given-names>
</name>
</person-group>
<article-title>MiR-486-3p targeting ECM1 represses cell proliferation and metastasis in cervical cancer</article-title>
<source/>Biomed. Pharmacother.
          <volume>80</volume>
<year>2016</year>
<fpage>109</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">27133046</pub-id>
</element-citation>
</ref>
<ref id="bib91">
<label>91</label>
<element-citation id="sref91" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steuer</surname>
<given-names>C.E.</given-names>
</name>
</person-group>
<article-title>An update on larynx cancer</article-title>
<source/>CA A Cancer J. Clin.
          <volume>67</volume>
<issue>1</issue>
<year>2017</year>
<fpage>31</fpage>
<lpage>50</lpage>
</element-citation>
</ref>
<ref id="bib92">
<label>92</label>
<element-citation id="sref92" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>T.B.</given-names>
</name>
<name>
<surname>Kjems</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Damgaard</surname>
<given-names>C.K.</given-names>
</name>
</person-group>
<article-title>Circular RNA and miR-7 in cancer</article-title>
<source/>Cancer Res.
          <volume>73</volume>
<issue>18</issue>
<year>2013</year>
<fpage>5609</fpage>
<lpage>5612</lpage>
<pub-id pub-id-type="pmid">24014594</pub-id>
</element-citation>
</ref>
<ref id="bib93">
<label>93</label>
<element-citation id="sref93" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.X.</given-names>
</name>
</person-group>
<article-title>Upregulation of circFLNA contributes to laryngeal squamous cell carcinoma migration by circFLNA-miR-486-3p-FLNA axis</article-title>
<source/>Cancer Cell Int.
          <volume>19</volume>
<year>2019</year>
<fpage>196</fpage>
<pub-id pub-id-type="pmid">31384171</pub-id>
</element-citation>
</ref>
<ref id="bib94">
<label>94</label>
<element-citation id="sref94" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savoy</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>P.M.</given-names>
</name>
</person-group>
<article-title>The dual role of filamin A in cancer: can't live with (too much of) it, can't live without it</article-title>
<source/>Endocr. Relat. Cancer
          <volume>20</volume>
<issue>6</issue>
<year>2013</year>
<fpage>R341</fpage>
<lpage>R356</lpage>
<pub-id pub-id-type="pmid">24108109</pub-id>
</element-citation>
</ref>
<ref id="bib95">
<label>95</label>
<element-citation id="sref95" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Mendoza</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Impact of the metabolic syndrome on mortality is modified by objective short sleep duration</article-title>
<source/>J Am Heart Assoc
          <volume>6</volume>
<issue>5</issue>
<year>2017</year>
</element-citation>
</ref>
<ref id="bib96">
<label>96</label>
<element-citation id="sref96" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoi</surname>
<given-names>W.</given-names>
</name>
</person-group>
<article-title>Muscle-enriched microRNA miR-486 decreases in circulation in response to exercise in young men</article-title>
<source/>Front. Physiol.
          <volume>4</volume>
<year>2013</year>
<fpage>80</fpage>
<pub-id pub-id-type="pmid">23596423</pub-id>
</element-citation>
</ref>
<ref id="bib97">
<label>97</label>
<element-citation id="sref97" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guehring</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Stimulation of gene expression and loss of anular architecture caused by experimental disc degeneration--an in vivo animal study</article-title>
<source/>Spine
          <volume>30</volume>
<issue>22</issue>
<year>2005</year>
<fpage>2510</fpage>
<lpage>2515</lpage>
<pub-id pub-id-type="pmid">16284588</pub-id>
</element-citation>
</ref>
<ref id="bib98">
<label>98</label>
<element-citation id="sref98" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W.L.</given-names>
</name>
</person-group>
<article-title>Role of miR-155 in the regulation of MMP-16 expression in intervertebral disc degeneration</article-title>
<source/>J. Orthop. Res.
          <volume>35</volume>
<issue>6</issue>
<year>2017</year>
<fpage>1323</fpage>
<lpage>1334</lpage>
<pub-id pub-id-type="pmid">27227700</pub-id>
</element-citation>
</ref>
<ref id="bib99">
<label>99</label>
<element-citation id="sref99" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>miR-486-5p inhibits inflammatory response, matrix degradation and apoptosis of nucleus pulposus cells through directly targeting FOXO1 in intervertebral disc degeneration</article-title>
<source/>Cell. Physiol. Biochem.
          <volume>52</volume>
<issue>1</issue>
<year>2019</year>
<fpage>109</fpage>
<lpage>118</lpage>
<pub-id pub-id-type="pmid">30790508</pub-id>
</element-citation>
</ref>
<ref id="bib100">
<label>100</label>
<element-citation id="sref100" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansson</surname>
<given-names>G.K.</given-names>
</name>
<name>
<surname>Hermansson</surname>
<given-names>A.</given-names>
</name>
</person-group>
<article-title>The immune system in atherosclerosis</article-title>
<source/>Nat. Immunol.
          <volume>12</volume>
<issue>3</issue>
<year>2011</year>
<fpage>204</fpage>
<lpage>212</lpage>
<pub-id pub-id-type="pmid">21321594</pub-id>
</element-citation>
</ref>
<ref id="bib101">
<label>101</label>
<element-citation id="sref101" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niculescu</surname>
<given-names>L.S.</given-names>
</name>
</person-group>
<article-title>MiR-486 and miR-92a identified in circulating HDL discriminate between stable and vulnerable coronary artery disease patients</article-title>
<source/>PLoS One
          <volume>10</volume>
<issue>10</issue>
<year>2015</year>
<object-id pub-id-type="publisher-id">e0140958</object-id>
</element-citation>
</ref>
<ref id="bib102">
<label>102</label>
<element-citation id="sref102" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bardin</surname>
<given-names>P.</given-names>
</name>
</person-group>
<article-title>Emerging microRNA therapeutic approaches for cystic fibrosis</article-title>
<source/>Front. Pharmacol.
          <volume>9</volume>
<year>2018</year>
<fpage>1113</fpage>
<pub-id pub-id-type="pmid">30349480</pub-id>
</element-citation>
</ref>
<ref id="bib103">
<label>103</label>
<element-citation id="sref103" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ideozu</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Microarray profiling identifies extracellular circulating miRNAs dysregulated in cystic fibrosis</article-title>
<source/>Sci. Rep.
          <volume>9</volume>
<issue>1</issue>
<year>2019</year>
<fpage>15483</fpage>
<pub-id pub-id-type="pmid">31664087</pub-id>
</element-citation>
</ref>
<ref id="bib104">
<label>104</label>
<element-citation id="sref104" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terlizzi</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>Clinical expression of cystic fibrosis in a large cohort of Italian siblings</article-title>
<source/>BMC Pulm. Med.
          <volume>18</volume>
<issue>1</issue>
<year>2018</year>
<fpage>196</fpage>
<pub-id pub-id-type="pmid">30577776</pub-id>
</element-citation>
</ref>
<ref id="bib105">
<label>105</label>
<element-citation id="sref105" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ideozu</surname>
<given-names>J.E.</given-names>
</name>
</person-group>
<article-title>Transcriptome profiling and molecular therapeutic advances in cystic fibrosis: recent insights</article-title>
<source/>Genes
          <volume>10</volume>
<issue>3</issue>
<year>2019</year>
</element-citation>
</ref>
<ref id="bib106">
<label>106</label>
<element-citation id="sref106" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukai</surname>
<given-names>N.</given-names>
</name>
</person-group>
<article-title>Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease</article-title>
<source/>Pediatr. Res.
          <volume>83</volume>
<issue>4</issue>
<year>2018</year>
<fpage>866</fpage>
<lpage>873</lpage>
<pub-id pub-id-type="pmid">29281614</pub-id>
</element-citation>
</ref>
<ref id="bib107">
<label>107</label>
<element-citation id="sref107" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.S.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors</article-title>
<source/>Blood
          <volume>125</volume>
<issue>8</issue>
<year>2015</year>
<fpage>1302</fpage>
<lpage>1313</lpage>
<pub-id pub-id-type="pmid">25515961</pub-id>
</element-citation>
</ref>
<ref id="bib108">
<label>108</label>
<element-citation id="sref108" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
</person-group>
<article-title>Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases</article-title>
<source/>Cell Res.
          <volume>18</volume>
<issue>10</issue>
<year>2008</year>
<fpage>997</fpage>
<lpage>1006</lpage>
<pub-id pub-id-type="pmid">18766170</pub-id>
</element-citation>
</ref>
<ref id="bib109">
<label>109</label>
<element-citation id="sref109" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giles</surname>
<given-names>K.M.</given-names>
</name>
</person-group>
<article-title>miRNA-7-5p inhibits melanoma cell migration and invasion</article-title>
<source/>Biochem. Biophys. Res. Commun.
          <volume>430</volume>
<issue>2</issue>
<year>2013</year>
<fpage>706</fpage>
<lpage>710</lpage>
<pub-id pub-id-type="pmid">23206698</pub-id>
</element-citation>
</ref>
<ref id="bib110">
<label>110</label>
<element-citation id="sref110" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>MicroRNA 486-3P as a stability marker in acute coronary syndrome</article-title>
<source/>Biosci. Rep.
          <volume>36</volume>
<issue>3</issue>
<year>2016</year>
</element-citation>
</ref>
<ref id="bib111">
<label>111</label>
<element-citation id="sref111" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goedert</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>NEURODEGENERATION. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Abeta, tau, and alpha-synuclein</article-title>
<source/>Science
          <volume>349</volume>
<issue>6248</issue>
<year>2015</year>
<fpage>1255555</fpage>
<pub-id pub-id-type="pmid">26250687</pub-id>
</element-citation>
</ref>
<ref id="bib112">
<label>112</label>
<element-citation id="sref112" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group>
<article-title>miR-486-3p influences the neurotoxicity of a-synuclein by targeting the SIRT2 gene and the polymorphisms at target sites contributing to Parkinson's disease</article-title>
<source/>Cell. Physiol. Biochem.
          <volume>51</volume>
<issue>6</issue>
<year>2018</year>
<fpage>2732</fpage>
<lpage>2745</lpage>
<pub-id pub-id-type="pmid">30562735</pub-id>
</element-citation>
</ref>
<ref id="bib113">
<label>113</label>
<element-citation id="sref113" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shibutani</surname>
<given-names>M.</given-names>
</name>
</person-group>
<article-title>Arid1b haploinsufficiency causes abnormal brain gene expression and autism-related behaviors in mice</article-title>
<source/>Int. J. Mol. Sci.
          <volume>18</volume>
<issue>9</issue>
<year>2017</year>
</element-citation>
</ref>
<ref id="bib114">
<label>114</label>
<element-citation id="sref114" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D'Gama</surname>
<given-names>A.M.</given-names>
</name>
</person-group>
<article-title>Targeted DNA sequencing from autism spectrum disorder brains implicates multiple genetic mechanisms</article-title>
<source/>Neuron
          <volume>88</volume>
<issue>5</issue>
<year>2015</year>
<fpage>910</fpage>
<lpage>917</lpage>
<pub-id pub-id-type="pmid">26637798</pub-id>
</element-citation>
</ref>
<ref id="bib115">
<label>115</label>
<element-citation id="sref115" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Serum miRNA expression profiling reveals miR-486-3p may play a significant role in the development of autism by targeting ARID1B</article-title>
<source/>Neuroreport
          <volume>29</volume>
<issue>17</issue>
<year>2018</year>
<fpage>1431</fpage>
<lpage>1436</lpage>
<pub-id pub-id-type="pmid">30260819</pub-id>
</element-citation>
</ref>
<ref id="bib116">
<label>116</label>
<element-citation id="sref116" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoyer</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>Haploinsufficiency of ARID1B, a member of the SWI/SNF-a chromatin-remodeling complex, is a frequent cause of intellectual disability</article-title>
<source/>Am. J. Hum. Genet.
          <volume>90</volume>
<issue>3</issue>
<year>2012</year>
<fpage>565</fpage>
<lpage>572</lpage>
<pub-id pub-id-type="pmid">22405089</pub-id>
</element-citation>
</ref>
<ref id="bib117">
<label>117</label>
<element-citation id="sref117" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Byon</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Papayannopoulou</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>MicroRNAs: allies or foes in erythropoiesis?</article-title>
<source/>J. Cell. Physiol.
          <volume>227</volume>
<issue>1</issue>
<year>2012</year>
<fpage>7</fpage>
<lpage>13</lpage>
<pub-id pub-id-type="pmid">21412774</pub-id>
</element-citation>
</ref>
<ref id="bib118">
<label>118</label>
<element-citation id="sref118" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>D.E.</given-names>
</name>
<name>
<surname>Kamran</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Orkin</surname>
<given-names>S.H.</given-names>
</name>
</person-group>
<article-title>Reawakening fetal hemoglobin: prospects for new therapies for the beta-globin disorders</article-title>
<source/>Blood
          <volume>120</volume>
<issue>15</issue>
<year>2012</year>
<fpage>2945</fpage>
<lpage>2953</lpage>
<pub-id pub-id-type="pmid">22904296</pub-id>
</element-citation>
</ref>
<ref id="bib119">
<label>119</label>
<element-citation id="sref119" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sankaran</surname>
<given-names>V.G.</given-names>
</name>
</person-group>
<article-title>Developmental and species-divergent globin switching are driven by BCL11A</article-title>
<source/>Nature
          <volume>460</volume>
<issue>7259</issue>
<year>2009</year>
<fpage>1093</fpage>
<lpage>1097</lpage>
<pub-id pub-id-type="pmid">19657335</pub-id>
</element-citation>
</ref>
<ref id="bib120">
<label>120</label>
<element-citation id="sref120" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lulli</surname>
<given-names>V.</given-names>
</name>
</person-group>
<article-title>MicroRNA-486-3p regulates gamma-globin expression in human erythroid cells by directly modulating BCL11A</article-title>
<source/>PLoS One
          <volume>8</volume>
<issue>4</issue>
<year>2013</year>
<object-id pub-id-type="publisher-id">e60436</object-id>
</element-citation>
</ref>
<ref id="bib121">
<label>121</label>
<element-citation id="sref121" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Han</surname>
<given-names>D.</given-names>
</name>
</person-group>
<article-title>Long noncoding RNA H19 indicates a poor prognosis of colorectal cancer and promotes tumor growth by recruiting and binding to eIF4A3</article-title>
<source/>Oncotarget
          <volume>7</volume>
<issue>16</issue>
<year>2016</year>
<fpage>22159</fpage>
<lpage>22173</lpage>
<pub-id pub-id-type="pmid">26989025</pub-id>
</element-citation>
</ref>
<ref id="bib122">
<label>122</label>
<element-citation id="sref122" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imig</surname>
<given-names>J.</given-names>
</name>
</person-group>
<article-title>miR-CLIP capture of a miRNA targetome uncovers a lincRNA H19-miR-106a interaction</article-title>
<source/>Nat. Chem. Biol.
          <volume>11</volume>
<issue>2</issue>
<year>2015</year>
<fpage>107</fpage>
<lpage>114</lpage>
<pub-id pub-id-type="pmid">25531890</pub-id>
</element-citation>
</ref>
<ref id="bib123">
<label>123</label>
<element-citation id="sref123" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di Ianni</surname>
<given-names>T.</given-names>
</name>
</person-group>
<article-title>Ultrasound/microbubble-mediated targeted delivery of anticancer microRNA-loaded nanoparticles to deep tissues in pigs</article-title>
<source/>J. Control. Release
          <volume>309</volume>
<year>2019</year>
<fpage>1</fpage>
<lpage>10</lpage>
<pub-id pub-id-type="pmid">31326463</pub-id>
</element-citation>
</ref>
<ref id="bib124">
<label>124</label>
<element-citation id="sref124" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chipman</surname>
<given-names>L.B.</given-names>
</name>
<name>
<surname>Pasquinelli</surname>
<given-names>A.E.</given-names>
</name>
</person-group>
<article-title>miRNA targeting: growing beyond the seed</article-title>
<source/>Trends Genet.
          <volume>35</volume>
<issue>3</issue>
<year>2019</year>
<fpage>215</fpage>
<lpage>222</lpage>
<pub-id pub-id-type="pmid">30638669</pub-id>
</element-citation>
</ref>
<ref id="bib125">
<label>125</label>
<element-citation id="sref125" publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Rana</surname>
<given-names>T.M.</given-names>
</name>
</person-group>
<article-title>Therapeutic targeting of microRNAs: current status and future challenges</article-title>
<source/>Nat. Rev. Drug Discov.
          <volume>13</volume>
<issue>8</issue>
<year>2014</year>
<fpage>622</fpage>
<lpage>638</lpage>
<pub-id pub-id-type="pmid">25011539</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>